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Many Drug Delivery Systems (DDS) have been developed over recent years to achieve 
the intended site-specific delivery of anticancer therapeutics to target tumor sites. For the 
delivery of small molecule anticancer drug to tumor tissues, many DDS formulations 
demonstrated significant toxicity towards cancer cells in vitro and even in vivo, but have been 
unsuccessful in clinical stages due to undesirable side effects that arise as a result of carrier 
instability. In addition, existing carriers suffer from low drug loading capacity leading to carrier 
inefficiency. On the other hand, for delivery of proteins and DNAs intracellularly, efficacy of 
such DDS is still not satisfactory, which may be attributed in part to inability to attain the desired 
stability to facilitate both transport and release. Thus the goal of a clinically approved vector 
remains elusive. In addition, few are equipped with cancer cell targeting ability. Complex 
formation between the therapeutic cargoes and the carrier may be an important consideration to 
overcome these issues. Many approaches have been explored to achieve optimal interaction 
between cargo and carrier either by chemical conjugation or physical interactions.  
Here, we are inspired to use green tea catechin (-)-epigallocatechin-3-gallate (EGCG), in 
the design of novel polymeric complexes for cancer therapy. First, EGCG has been widely 
reported to possess anti-oxidative and anti-carcinogenic effects. Furthermore, the multiple-ringed 
structure of EGCG confers it the ability to interact favorably with small molecular anticancer 
drugs, protein and DNA through a wide range of non-covalent interactions including 
hydrophobic, hydrogen bonding and π-π stacking. Thus incorporating EGCG in polymer carrier 
system is predicted to enhance interactions between cargo and carrier, leading to better loading, 
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higher stability of the carrier formulation. To this end, two different polymer carrier systems 
based on EGCG for cancer therapy were developed.  
The first drug carrier system was an amphiphilic polymer comprising of two EGCG 
molecules conjugated to the terminal end of linear polyethylene glycol (PEG) chain to form 
PEG-EGCG conjugates. Self-assembled PEG-EGCG micelles physically encapsulating the small 
molecule anticancer drug, doxorubicin (Dox) were prepared. As a result of strong interactions 
between Dox and EGCG, these nanosized PEG-EGCG micelles were observed to have an 
exceptionally high drug loading capacity, high stability and slow drug release. Further evaluation 
in a murine xenograft tumor model revealed that these micelles achieved tumor growth inhibition 
with no significant loss in body weight. In addition, micelle exhibited higher anticancer efficacy 
and reduced toxicity compared to optimal dosages of two clinically relevant Dox formulations 
such as free Dox and PEGylated liposomal Dox - DOXIL.  
In the second system, EGCG was grafted onto the side chain of hyaluronic acid (HA) to 
synthesize HA-EGCG conjugates. EGCG was utilized for its strong interactions with protein. 
HA was exploited for its ability to target CD44 receptors overexpressed on many cancer cells. 
HA-EGCG conjugate self-assembled spontaneously in aqueous solution with the protein 
Granzyme B (GzmB) and linear polyethyleneimine (PEI) to form a nanogel complex. The 
nanogel complexes selectively delivered GzmB intracellularly into the cytoplasm of cancer cells 
via CD44 receptor-mediated endocytosis, and subsequently resulted in apoptosis of cancer cells.  
HA-EGCG conjugates were also investigated for gene delivery. Self-assembled HA-
EGCG/PEI/DNA nanogel complexes were prepared. Strong interactions between HA-EGCG and 
PEI/DNA gave rise to increased stability of complexes. These complexes achieved significant 
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enhancement in gene transfection than PEI/DNA binary complexes in CD44 overexpressing 
cancer cells as a result of increased uptake via CD44 receptor-mediated endocytosis. HA-EGCG 
nanogel complexes also showed superior transfection efficiency over HA complexes because of 
improved stability. Thus, we expect that this nanogel system could potentially be used to achieve 
targeted delivery of apoptosis inducing suicide genes to kill cancer cells. 
In summary, we developed two EGCG based polymeric carrier systems and demonstrated 
their efficacy in delivery of small molecule drugs, protein and DNA for cancer therapy. They 
have the potential to be effective strategies to potentially overcome the challenges of current 
DDS.       
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Cancer is generally considered a growth system malfunction that originates within a 
patient's body. It manifests in many forms but is governed by one universal characteristic: the 
ability to divide and proliferate indefinitely. In normal tissues, this uncontrollable growth is 
offset by tumor-suppressor mechanisms in which diseased or infected cells go through a process 
programmed cell death or “apoptosis” [1]. In cancers, many of the cells lost the ability to 
undergo apoptosis thus leading to disruption of the balance between self-renewal and destruction 
[2]. With the impairment of apoptosis signaling, cancer cells continuously divide to create large 
cell masses also known as tumors. The exact reasons for signal failure in cancer are usually 
unclear but can be attributed to alterations in multiple complex cellular pathways [3].  
Unlimited and unregulated cell growth is detrimental because it can cause the disruption 
of normal tissues and organs function by competing with healthy cells for the space, supply of 
oxygen and nutrients. In addition, cancers are malicious because they can spread throughout the 
body by invasion and metastasis [4, 5]. Invasion refers to the migration by cancer cells into 
tissues that are adjacent to them and directly causing them to become cancerous. On the other 
hand, metastasis refers to the permeation and distribution of cancer cells into lymphatic and 
blood vessels, which then transport them by the bloodstream to invade other normal tissues 
elsewhere in the body.  
While numerous treatments have been developed to treat and delay the course of the 
disease, cancer currently has no complete cure. Drug treatment has only been met with limited 
success because cancer cells have been found to be extremely heterogeneous. Many different 
types of cancer cells exist within a tumor and  different cancers  may vary in characteristics and 
properties (e.g. cellular interactions and signaling complexities) [6, 7]; they either mutate or 
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develop drug resistance after prolonged drug exposure [8, 9]. While drug treatment may kill a 
large percentage of cells, even a small portion of resistant cells can cause cancer to relapse and 
regrowth. And it was discovered that drug resistance could also be mediated by cancer stem cell 
populations that exist within solid tumors [9]. In addition, it is well known that cancer cells can 
migrate from their original location and metastasize to reach various parts of the body [10]. All 




1.2. Cancer treatments 
 It was estimated that there were 14.1 million cancer cases and 8.2 million cancer deaths 
worldwide in 2012 and it is expected to rise to 19.3 million new cancer cases per year by 2025 
[11]. The four most common causes of cancer - lung, liver, stomach, and bowel - account for 
nearly half (46 %) of all cancer death. Despite the prevalence of cancer, the progress in disease 
management has been encouraging. The 5-year relative survival rate for all cancers in the US 
diagnosed between 2003 and 2009 was 68 %, up from 49 % in 1975 - 1977 [12], in large part 
due to the tremendous progress in diagnosis and treatment. Currently, the most common 
treatments of cancer include surgery, radiation therapy and chemotherapy. 
1.2.1. Surgery 
Surgery is the most established treatment for cancer and involves an invasive operation in 
which the cancerous tissue is removed. Common examples of surgical procedures for cancer 
include mastectomy for breast cancer and pneumonectomy (entire lung removal) or lung 
segmentectomy (removal of portions of lobe) for non-small cell lung cancer. Theoretically, 
cancers can be cured if all infected cells are removed by surgery, but this is not always possible. 
Often, cancer cells metastasize and spread rapidly to other parts of the body. Unless surgery is 
performed prior to any metastasis, complete surgical excision of cancer is impossible [13]. 
Nevertheless, surgery offers the greatest chance for survival, especially for early stage cancer 
patients. Performing tumor excision by surgery is also very challenging, especially in sensitive 
areas such as the brain or in areas where the access to the tumor is impeded. But with 
advancements in surgical techniques and instrumentation, surgeons have been able to overcome 
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some of these difficulties.  One example is the use of ultrasound to assist in surgical procedures 
in hard-to-reach areas and this has led to improved clinical outcomes [14]. 
1.2.2. Radiation therapy 
Radiation therapy refers to the method of killing cancer cells by a beam of high energy 
radiation. X-rays and gamma rays are the common types of radiation used [15]. The radiation 
may be delivered by a machine from outside the body (external-beam radiation therapy), or it 
may come from radioactive material placed in the body near cancer cells or injected into the 
blood stream (internal radiation therapy, also called brachytherapy). Radiation therapy destroys 
cancer cells by damaging their DNA, thus making it impossible for these cells to continue to 
grow and divide. However, radiation kills cells indiscriminately so any normal cells in the 
vicinity of the beam will be harmed as well. In order to reduce damage to nearby healthy tissue, 
radiation therapy is usually given in many fractions, so as to allow healthy tissue to recover 
between fractions. Radiation dosage is also adjusted carefully depending on the radiosensitivity 
of cancer and the presence of surrounding organs. Some acute side effects that may result from 
radiation therapy include skin irritation in the areas surrounding irradiated region and hair loss 
while long term adverse effects include scarring, fibrosis and memory loss [16, 17].  
1.2.3. Chemotherapy 
Chemotherapy generally refers to the use of cytotoxic drugs to kill cancer cells. This 
form of cancer treatment arose in the last century following the progress in drugs synthesis and 
discovery led by the pharmaceutical industry [18]. Many forms of drugs are used clinically for 
treatment including small molecule compounds and proteins. Patients undergoing chemotherapy 
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take these drugs at regular intervals to keep cancer under control. However, chemotherapeutic 
drugs typically exhibit toxicity against all fast-growing, proliferative cells. While the 
uncontrollable growth of cancer cells makes them suitable targets for these drugs, many active 
healthy cells may suffer collateral damage, leading to multiple side effects such as hair loss, 
weakness and bleeding [19]. Furthermore, many stand-alone chemotherapy drugs suffer from 
numerous other problems including rapid in vivo metabolism and/or excretion, failure to migrate 
and partition into deep cancer tissues, and nonspecific uptake by healthy cells as they circulate in 
the bloodstream. Very often, a large percentage of cytotoxic anticancer drugs administered to the 
patient does not reach the tumor site but rather is distributed throughout the rest of the body. The 
severity of toxic side effects from drugs migrating to healthy tissues further limits the dosage 
drug to be administered and compromise the efficacy of treatment. As such, a drug-free period is 
normally necessary following chemotherapy. This reduces possibility of complete eradication as 
cancer cells revive during that time [20].  
Even though survival rates have improved with the advent of conventional chemotherapy, 
the clinical outcomes thus far are modest at best. Nonetheless as we continue to make progress in 
understanding of the pharmacokinetics and pharmacodynamics of anticancer drugs as well as 
underlying principles of cancer biology, it is expected that the efficacy of chemotherapy will be 
increased significantly.  
 
1.2.3.1. Conventional anticancer drugs 
Among the various chemotherapeutic drugs, conventional anticancer compounds are the 
most established [18, 21]; with the first documented chemotherapy drug being nitrogen mustards 
in the treatment of lymphoma in 1946 [22]. Later on, anti-metabolites such as methotrexate was 
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discovered to cure choriocarcinoma [23]. These conventional anticancer drugs are typically of 
small molecular weight (Molecular Weight (Mw) < 1000 g/mol), hydrophobic and can diffuse 
across membranes (both cell and nuclear) readily and interrupt cellular function by various 
mechanisms, as listed in Table 1-1. Some have modes of action within the nucleus and impact 
the DNA directly [24, 25]. For instance, doxorubicin (Dox) is a topoisomerase II inhibitor that 
intercalates DNA and hinders replication; cisplatin is an alkylating agent that crosslinks DNA 
while methotrexate and gemcitabine are anti-metabolites that interfere with DNA and RNA 
production by purine synthesis inhibition and pyrimidine substitution respectively. Other 
conventional small molecule drugs disrupt components of the cytoskeleton in the cytoplasm  [24, 
25].  For example, paclitaxel belongs to the category of anti-microtubule agents that inhibit cell 
division by stabilizing microtubule formation.   
One issue with these conventional anticancer compounds is their limited solubility. Since 
most of the drugs are given intravenously, inability to dissolve in aqueous solution limits the 
amount of drug that can be administered. For instance, the surfactant Cremophor EL 
(polyethoxylated castor oil) is currently used as an excipient to dissolve paclitaxel [26]. Even 
though Cremophor EL successfully overcome the solubility issue, using this formulation has led 
to a new set of unwanted side effects such as hyperlipidaemmia, abnormal lipoprotein 
aggregation of erythrocyte, neurotoxicity and cardiotoxicity [26].  
But by far the biggest problem with using these classical chemotherapeutic drugs is high 
toxicity toward normal cells as mentioned previously. One approach to overcome this problem is 







Table 1-1. Types of conventional anticancer drugs. 
Generic Trade Name Mw (g/mol) Class Target 





Cisplatin Platinol 300 Alkylating agent DNA binding 
Gemcitabine Gemzar 263 Anti-metabolites 
DNA/RNA 
synthesis 
Methotrexate Trexall 454 Anti-metabolites 
DNA/RNA 
synthesis 






1.2.3.2. Targeted chemotherapy 
With the goal of selectively killing cancer cells in mind, a new generation of molecular-
targeted anticancer therapeutics is being developed. They are designed specifically to interfere 
with cancer cellular functions, such as inhibition of growth factor proteins, or specific molecules 
that are key players in signal transduction, in the cell cycle or in other important cellular 
pathways of cancer cells [27, 28]. Generally, there are two classes of therapeutic agents for 
targeted cancer treatment - small molecule anticancer compounds and monoclonal antibodies. 
1.2.3.2.1. Targeted small molecule anticancer drugs 
Targeted small molecule anticancer drugs are synthetic molecules designed to target 
cancer biomarkers. Most notable among these biomarkers are protein tyrosine kinases (PTKs), an 
important family of signaling proteins involved in many protein-protein interactions. Examples 
of PTKs include: members of the human epidermal growth factor receptor family (HER1-4), 
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vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor 
(PDGFR), epidermal growth factor receptor (EGFR) and mast/stem cell growth factor receptor 
(SCFR/c-KIT) [28, 29]. PTKs are involved in cellular growth, proliferation, migration, 
differentiation, and apoptosis [30]. Currently several inhibitors of PTKs have been approved by 
the FDA for treatment of specific types of cancer (Table 1-2), and others are being studied in 
clinical trials. One of the most successful small molecule tyrosine kinase inhibitor – Imatinib, 
was approved by FDA in 2001 for the treatment of chronic myeloid leukemia. It was found to 
drastically improve patient response and survival rate [31].   
In general these targeted anticancer drugs are less toxic than conventional drugs and their 
side effects are usually mild, including nausea, headache, fluid retention [32]. However one 
concern with regards to their use is the development of resistance to these inhibitors, which 
usually arise as a result of mutations to the protein kinases [33, 34]. It is proposed that a 
combination therapy with a second agent whose mechanism of action is different from the 
original drug could possibly overcome this problem [35].  
Table 1-2. Types of targeted small molecule anticancer drugs. 
Generic Trade Name Mw 
(g/mol) 
Target Cancer Type 
Imatinib Gleevec 494 
PDGFR, c-KIT, 
Abelson kinase 
Chronic Myeloid Leukemia, 
Gastrointestinal Stromal 
Tumor 




Tumor, Renal Cell 
Carcinoma 
Erlotinib Tarceva 393 EGFR Non-small Cell Lung 
Cancer, Pancreatic Cancer 








1.2.3.2.1. Monoclonal antibodies 
Besides small molecule drugs, monoclonal antibodies (mAb)s are another class of 
chemotherapeutic agents. They are proteins produced by immune cells that bind to specific target 
molecules – antigens overexpressed on cell surfaces. Many tumor antigens have been identified 
as possible targets for mAbs. For instance, Trastuzumab binds to Her2 receptor overexpressed in 
some types of breast cancer cells and Cetuximab binds to epidermal growth factor receptor 
(EGFR) that is overactive in many cancer cells. Both result in disruption of proliferation 
signaling. On the other hand, Bevacizumab inhibits the function of the vascular endothelial 
growth factor (VEGF) protein that is needed for angiogenesis (Table 1-3).  
Despite the high selectivity of these novel targeted chemotherapeutics, a range of 
previously unknown and unpredictable side effects has emerged. Most of these side effects arise 
as a result of specific molecular target in normal tissues being inhibited or modulated by the 
drugs [28]. Inhibition of EGFR, which is involved in regulation of cell proliferation, leads to 
skin-related problems such as papulopustular eruption in patients [29] while targeting VEGF 
pathway affects normal blood vessel formation and leads to side effects including hypertension, 
arterial thromboembolic events [30].  
Table 1-3. Types of monoclonal antibodies. 
Generic Trade Name Type Class Target 
Bevacizumab Avastin mAb Anti-angiogenesis VEGF 










1.2.3.3. Anticancer drugs in development – proteins and DNA/siRNA for intracellular 
targets 
A majority of the targeted chemotherapeutics developed were focused on extracellular 
targets, especially antibody-receptor binding interactions. This is an area where there is potential 
for new drug discovery is in regulating molecules that play key roles in the intracellular 
pathways of cancer cells. The most studied approach is to trigger cell death in cancer cells by 
activating apoptosis.[36, 37] Cancer cells proliferate uncontrollably due to changes in cell-death 
signaling pathways, in particular mutation or defects to the Bcl-2 family proteins and p53 
signaling. One strategy is to regulate gene expression by gene transfection, RNA interference 
using siRNA (small interfering RNA), antisense oligonucleotides and DNA aptamers. Thus far, 
there has been some initial success in cancer treatment. Most notably the Bcl-2 antisense 
oligonucleotide has shown anticancer efficacy in combination with other drugs or radiation 
therapy [38, 39]. Small molecule compounds and recombinant proteins have also been explored 
to target molecules involved in the apoptosis pathway including various caspases and 
cytochrome C (Cyt C) [40, 41]. For example, caspase-3 mediated cell killing is exploited for 
cancer therapy in which a target antigen is used to induce activation of the caspase-3 moieties 
bound to the antibody [42]. 
1.2.4. Delivery of chemotherapeutic drugs  
Even though we are equipped with more effective anticancer therapeutics, their clinical 
outcomes have been modest. A shortfall in the efficacy of most drugs is their difficulty in 
completing their journey to tumor cells upon intravenous administration. While in circulation the 
drug must be able to bypass the routes of clearance including renal filtration, liver metabolism, and 
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the organs of the reticulo-endothelial system (RES). RES comprises of phagocytic cells such as 
monocytes and macrophages that are responsible for the routine removal of foreign substances 
from the blood stream [43]. Upon overcoming these obstacles, the remaining drugs may 
encounter the tumor vasculature and some of those may successfully diffuse out of the blood 
vessels to enter the tumor interstitial space [44]. The drug that has made it to this point must then 
penetrate into the tumor and encounter a target cell. For drugs with intracellular targets, they 
must then cross the phospholipid bilayer membrane, and finally localize in the cellular 
compartment relevant to the drug’s mechanism of action in sufficient concentrations to cause cell 
death [44].  
To address these limitations and improve performance of stand-alone drug, drug delivery 





1.3. Drug Delivery Systems (DDS) 
1.3.1. Overview  
A DDS (drug delivery system) is defined as a “formulation or a device that enables the 
introduction of a therapeutic substance in the body and improves its efficacy and safety by 
controlling the rate, time, and place of release of drugs in the body” [45]. It includes the process 
of administration, release and finally transport of the active therapeutic across biological 
membranes to site of action. DDS exists in many forms, oral capsules or protective coatings, 
implantable drug reservoirs, controlled release devices like hydrogels, or formulations such as 
drug carriers and they can be introduced via many anatomical routes including intravenous, 
subcutaneous, intra-muscular and transdermal [45, 46]. In this thesis, the scope would be mainly 
focused on DDS for anticancer therapeutics. 




Figure 1-1. Pharmacologist interpretation of the “Magic 
Bullet” concept for chemotherapy where the goal of is to 
selectively deliver drugs to target tumor instead of healthy 
tissues and organs. 
 
 
The criteria for the ideal DDS was first proposed by Paul Ehrlich in the early 19th century 
when he first introduced the term “Magic Bullet”. This concept was first proposed by him in 
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immunology to describe the specificity of receptor antigen binding [47, 48]. Later on scientists 
adapted his idea of the magic bullet to illustrate the exclusive and highly specific manner in 
which a compound reaches its target [49]. Thus in the case of cancer drug delivery, the DDS had 
to bring the drug all the way to the tumor site where it exerts its biological activity while 
avoiding all healthy tissues along its journey (Figure 1-1) [50]. In this way, cytotoxic drugs will 
be directed only to tumors where they exert antitumor activity while the toxic effects on non-
target site would be kept to a minimum.  
One hundred years later, the vision of “Magic Bullet” still eluded us and the goal of 
achieving perfectly targeted DDS is far from realization [51]. Nevertheless, significant progress 
has been made along the way toward designing carriers for tumor-specific delivery.  
1.3.3. Covalent drug delivery systems  
 
Figure 1-2. Ringsdorf’s model for polymer-drug conjugate that comprises of the drug, solubilizing group, 
targeting moiety and cleavable linker bound to a polymer backbone.   
To facilitate drug delivery to tumors, many drug delivery systems designs were explored. 
In 1975, Helmut Ringsdorf first proposed a general model for polymer-drug conjugate type of 
DDS using synthetic polymer for low-molecular weight drugs [52]. The drug was chemically 
15 
 
conjugated onto the polymer backbone together with other solubilizing groups and targeting 
moeties in a pendant chain configuration. In addition, a spacer was introduced between the drug 
and the polymer to facilitate release of drug after cellular uptake of the conjugates. Thereafter 
many polymer-drug conjugates were developed based on this model. In particular, Kopecek and 
his colleagues have done extensive research using the poly(N-(2-hydroxypropyl) 
methacrylamide) (HPMA) homopolymer as the polymer backbone. In one system, the anticancer 
drug Dox was conjugated onto poly(HPMA) via enzyme-degradable (Gly-Phe-Leu-Gly) linkages 
has been shown to have enhanced antitumor effect and prolonged survival time as compared to 
free drug [53, 54]. This promising polymer-drug conjugate has since progressed to Phase 2 of 
clinical trials [55]. Following the initial success, the usage of HPMA copolymers in polymer-
drug conjugates has been further expanded by many other groups that made various 
modifications including switching to other pendant drugs such as cisplatin [56] and camptothecin 
[57], utilizing targeting molecules such as antibody fragments [58] as well as adopting a pH-
responsive hydrazone linkage between the drug and the polymer [59, 60]. 
Despite the success of polymer-drug conjugates, one drawback for this type of DDS is 
the need for chemical modifications on the therapeutic payload since conjugation of drug onto 
polymer requires the formation of a covalent bond. Not all cargoes could be intact after 
conjugation. For macromolecules such as proteins, the structural conformations are important. 
Functionalization may potentially affect the three-dimensional structure of the protein and 
disturb its substrate binding sites or recognition areas resulting in loss of activity [61, 62].  
A strategy to overcome this is to exploit the interactions between the modalities on the 
carriers and drugs to form non-covalent complexes. They can be prepared by controlled mixing 
of samples and followed by spontaneous self-assembly of the complexes over time [63, 64].  
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1.3.4. Non-covalent complexes for drug delivery 
Formation of non-covalent inclusion complexes depends on the presence of physical 
interactions between the carrier and the drug payload, including van der Waals, hydrophobic 
interaction, H-bond, π-π stacking and electrostatic interactions [65]. A commonly used non-
covalent complex is the polyethyleneimine (PEI) and DNA ionic complex, based on the 
condensation of anionic DNA with the cationic polymer [66]. In addition, the strength of 
interactions can be tuned by chemical modifications of the carrier. Hydrophobic functionalities 
can be grafted onto polymer backbones to enhance the interaction of carrier with hydrophobic 
drugs. 
 
Figure 1-3. Representative types of non-covalent complexes for anticancer drug delivery. 
Many classes of non-covalent polymeric complexes have emerged, such as polymeric 
micelles, liposomes, dendrimers and nanogels [67]. Among them, the two types of non-covalent 
polymeric complexes that are highlighted in this thesis are polymeric micelles and nanogels. 
Nanogels are composed of cross-linked three-dimensional polymer chain networks that are 
formed via covalent linkages or self-assembly processes [68]. In particular, hydrophilic polymers 
such as polysaccharides and poly(amino acids) are modified using hydrophobic moieties, such as 
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cholesteryl [69-71] and deoxycholic acid [72, 73] in order to form drug loading reservoirs where 
these hydrophobic molecules can reside. On the other hand, polymeric micelle has a core-shell 
structure that typically comes in the form of a block copolymer with one block forming the 
hydrophobic core and the other the hydrophilic corona or shell. The hydrophilic block is 
typically made up of poly(ethylene glycol) (PEG), whereas the hydrophobic block comprises of 
poly(amino acids) such as poly(aspartate) [74, 75] and poly(lactide-co-glycolide) (PLGA) [76, 
77]. One common method of preparing polymeric micelles is by mixing the hydrophobic drug 
and polymer in organic solvent followed by dialysis against water to induce self-assembly of 
micelles [78]. In the micelle conformation, the inner hydrophobic core encapsulates the poorly 
water-soluble drug, while the outer hydrophilic corona provides solubility and protects the drug 
from being degraded in the aqueous environment [78, 79]. 
1.3.5. Passive targeting by EPR effect 
Structure features are important design considerations for drug delivery systems. Nano-
sized carrier formulations have been gathering more interest recently due to the advantage of 
passive targeting [80]. In the field of drug delivery, passive targeting generally refers to the 
passive accumulation of the drug carriers at the target tumor site. That is achieved by the EPR 
(Enhanced Permeability and Retention) effect [81-85]. Maeda et al. first introduced this concept 
of EPR effect in 1986 when they found that by conjugation of the anticancer protein 
neocarzinostatin (NCS) to a copolymer of styrene and maleic acid anhydride (SMA) to form 
SMANCS, they could achieve a much greater accumulation of (5-fold increase compared to free 
NCS at 24 hours) NCS in tumor tissues [81-83].  The explanation they proposed was that long 
circulating nanosized macromolecule drug carriers (< 200 nm) could be preferentially directed to 
tumor sites because of the tumor’s leaky vasculature. In tumor sites, poorly developed vascular 
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endothelium due to excessive pro-angiogenic signaling and rapid growth of tumor and blood 
vessels creates much larger pores (400 nm - 1 µm) as compared to capillary pores of 1 nm [86, 
87]. In addition, the poor lymphatic drainage at the tumor tissues as a consequence of physical 
forces arising from cancer and stromal cell proliferation transferred by the interstitial matrix also 
leads to build-up of the carriers. Ideally, upon reaching the tumor site the nanoparticle carriers 
would permeate into the tumor vasculature by the enlarged pores and they would accumulate at 
the tumor tissue due to the lack of lymphatic clearance. Subsequently, the drugs that are 
encapsulated within the carriers would gradually diffuse into tumor tissues and kill the cells.  
Since its discovery, EPR strategy has been at the heart of the design criteria of many 
nanoparticle drug delivery systems. Kataoka et al. developed polymeric micelles of size range 
100 - 200 nm encapsulating the anticancer drug Dox [74, 75, 88].  By leveraging on the EPR 
effect, they successfully demonstrated that micelles could selectively accumulate in tumor (the 
drug concentration in tumor was 2-fold that of free drug) and inhibit tumor growth in mice 
models [74, 89]. While passive targeting by using nano-sized drug carriers has become an 
important strategy for anticancer drug delivery, there are still other architectural features of 
carriers to consider for in vivo application.   
1.3.6. Structural design considerations for drug carrier design in vivo 
It is well-known that long blood circulation time is a pre-requisite [81, 90] for EPR 
effect. Many stand-alone chemotherapy drugs suffer from unfavorable biodistribution upon 
intravenous administration - they are rapidly cleared from circulation. By packaging drugs and 
presenting them in a different form, drug delivery systems could significantly improve the 
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pharmacokinetics and biodistribution of stand-alone drugs [91, 92]. However, it is important to 
note that several structural aspects of carriers can also influence the pharmacokinetics greatly. 
1.3.6.1. Size 
In order for a nanoparticle to exhibit prolonged circulation, the particle size has to be 
above the renal filtration cutoff size of 5.5 nm, observed using quantum dots [93]. The maximum 
size of particles is influenced by tumor vasculature and splenic filtration. As mentioned earlier, 
pores in tumor endothelium can vary from 400 nm - 1 µm while splenic clearance has a smaller 
size restriction. Particles larger than 200 nm in diameter will have difficulty passing through the 
inter-endothelial slits of sinusoidal spleen with width rarely exceeding 200 - 400 nm [94]. 
Furthermore, foreign particles can be recognized by opsonin proteins present in circulation. In a 
process known as opsonization, they adsorb onto surface of particles and present them to 
macrophages and monocytes at RES organs for phagocytosis [95]. It has been demonstrated by 
several groups that nanoparticles above 200 nm in diameter are readily recognized by opsonin 
proteins and subsequently cleared by the liver and spleen [96, 97].  
Therefore it is generally believe that nanoparticles in the range of 20 – 200 nm would be 
ideal for anticancer drug delivery [98]. The effect of size in this range on pharmacokinetics and 
biodistribution has also been explored but with inconclusive results. Lee et al. found that 25 nm 
poly(ethylene glycol)-block-poly(ε-caprolactone) (PEG-b-PCL) block copolymer micelles was 
cleared faster from the plasma compared to 60 nm micelles (2.2-fold decrease in T1/2), leading to 
an almost 2-fold decrease in their total tumor accumulation [99]. When Zhang et al. compared 
the pharmacokinetics of 20, 40 and 80 nm gold nanoparticles, 20 nm particles showed the 
longest blood circulation half-life and lowest RES uptake among them leading to significantly 
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higher tumor uptake than the other nanoparticles [100]. The discrepancies in the findings suggest 
that the relationship between size and blood circulation time is complex and other factors such as 
nanoparticle composition may also influence the pharmacokinetics of carriers.   
Particle size also has a direct influence on tumor accumulation. In one study, Yue et al. 
reported that 36 nm and 72 nm fluorescently-labeled poly (ethylene glycol)-b-poly(l-lactide-co-
2-methyl-2-hydroxy oxycarbonyl-propylene carbonate) [MPEG-b-P(LA-co-MHC)] micelles 
showed similar tumor tissue uptake but higher than 112 and 136 nm micelles [101]. Cabral et al. 
went further to show that while all sub-100 nm polymeric micelles carrying oxaliplatin had 
similar efficacy on highly permeable colorectal cancer; in poorly permeable pancreatic tumors, 
only the 30 nm micelles had antitumor activity [102]. They attributed this difference to the 
ability of the smaller 30 nm micelles to penetrate deeper into tumors with less porous 
vasculature. Thus smaller nanoparticles may be more suitable for passive targeting to less 
permeable tumors.   
1.3.6.2. Surface charge 
The overall charge on a surface of a particle, which is measured as zeta potential (ξ), can 
influence the pharmacokinetics and biodistribution significantly. In general, negative particles (ξ 
≤ 10 mV) exhibit strong RES uptake, and positive particles (ξ ≥ 10 mV) will induce serum 
protein aggregation: neutral nanoparticles (within ± 10 mV) induces the least RES uptake and 
have the longest blood circulation time [98]. Levchenko et al. reported that liposomes exhibiting 
ξ ~ 40 mV exhibited more than 90% clearance in 10 min compared to 10% clearance for neutral 
(ξ ± 10 mV) liposomes [103]. Xiao et al. also demonstrated that nanoparticles with high positive 
(ξ ≥ 20 mV) or negative surface charge (ξ ≤ 20 mV) were efficiently opsonized and cleared by 
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the liver from the blood circulation. In addition, Zhang et al. also found that positively charged 
complexes that form aggregates with serum proteins can lead to transient embolism in the lung 
capillaries [104]. 
1.3.6.3. Surface decoration by PEG  
Surface decoration or coating is another important feature of nanoparticle carriers. Once 
administered intravenously, the circulating drug carriers are exposed to many blood components 
such as plasma proteins.  As a result of protein opsonization and clearance by the RES organs 
[43], a large proportion of drug carriers would be cleared from the body without ever reaching 
the tumor tissue. In order to minimize opsonization and impart a stealth-shielding effect, 
hydrophilic PEG chains have been grafted onto the surface of nanoparticle carriers [95, 105]. 
The highly flexible PEG brushes rapidly switch from one conformation to the next providing a 
steric hindrance effect to repel protein attachment as well as inhibition of inter-molecular 
aggregation [106, 107]. As an additional benefit, attachment of PEG also helps to improve 
solubility of many hydrophobic drugs. PEGylated carriers have been demonstrated to increase 
blood circulation and reduce RES sequestration and in turn efficacy of treatment [108]. For 
instance, Sadzuko et al. found that PEGylation of liposomes led to a 3-fold reduction in RES 
uptake, a 6-fold higher plasma area under the curve (AUC), and a 3-fold increased tumor uptake 
of a liposomal drug [109]. Furthermore, it was also reported that the PEGylated liposomal carrier 
DOXIL® has an much improved elimination half-life time of 55 hours and an AUC of 900 
µghml-1 in patients, as compared to the non-PEGylated formulation - Myocet® with a half-life of 
2.5 hours and AUC of 45 µghml-1 [110, 111]. 
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The density of PEG grafting also affected “Stealth” property. Essa et al. reported that an 
optimal 4 - 7 % PEG grafting density (mol/mol of lactic acid monomer) of poly(lactic acid) 
(PLA) could significantly reduce macrophage uptake [112].  Similarly, Gref et al. examined 
surface properties of PEG-PLA block copolymers also observed that PEG content of between 2 - 
5 wt % of to be the optimal value for resisting protein adsorption [113]. These studies indicate 
that surface modification with a small amount of PEG is sufficient to confer “Stealth” property 
and there is no additional benefit with increase in PEG content.   
 
Figure 1-4. (a) Passive targeting of nanoparticle carriers containing anticancer drugs based on the Enhanced 
Permeability and Rentention (EPR) effect. Angiogenesis leads to large gaps between the endothelial cells in 
tumor blood vessels, leading higher accumulation of drug in tumors. (b) Active targeting based on ligand-
receptor interaction to increase specificity of delivery. 
1.3.7. Active targeting  
Active targeting can be defined as “imparting to a nonspecific drug affinity towards its 
target by binding this drug with another molecule capable of specific recognition and binding to 
a target site. [114] ” For anticancer drugs that have difficulty to cross the cancer cell membrane, 
the task of DDS is even more challenging as transporting them to the tumor site is insufficient. 




targeting, these drugs still have to be taken up by the cells to their site of action. Hence active 
targeting strategy aims to exploit ligand-receptor, antigen–antibody and other forms of molecular 
recognition to deliver the drug to specific cells [114, 115]. For cancer therapy purposes, active 
targeting is especially beneficial because by improving the nanoparticle carrier’s selectivity for 
cancer cells, it can potentially minimize the delivery of toxic drugs to healthy tissues and 
improve therapeutic outcome [116].  
The overexpression of various receptors on the surface of cancer cell or tumor endothelial 
membrane [117] has inspired the design of many active targeting moieties against them. In 
particular, folate and transferrin ligands are among the most well-studied. As folate receptor is 
overexpressed in a variety of tumors especially ovarian cancer (80 - 90 %) [118] and binds folate 
molecule with extremely high affinity (KD ~ 10-9) [119], it has been used widely for tumor 
targeting. Yoo et al. reported the synthesis of folate receptor-targeting Dox micelles by 
conjugating folate moiety and Dox on either terminals of PEG-PLGA block copolymer 
respectively. These targeted micelles showed higher cellular uptake in vitro and greater tumor 
regression and consistently higher Dox accumulation (about 1.3-fold at 24 and 48 hours) in 
tumors compared to non-targeted micelles [76].  
Transferrin (Tf) receptors, which are involved in the regulation of cell growth, are also 
highly expressed on cancer cells. Suzuki et al. found that Tf conjugated PEG-liposomes carrying 
the drug oxaliplatin decreased tumor volume more than non-targeted PEG-liposomes [120]. In 
addition, concentration of delivered drug in tumor was higher and maintained in the tumor for 72 
hours after intravenous injection. The effect of Tf-targeting was also observed by Bartlett et al. 
They prepared Tf-targeting inclusion nanoparticle complexes containing luciferase-silencing 
24 
 
siRNA using Tf modified PEG-adamantane and β-cyclodextrin-polycation [121, 122]. Tumor 
luciferase activity in mice treated with Tf-targeted nanoparticles was 50 % lower than that in 
mice treated with non-targeted nanoparticles [122].  
While active targeting is a promising strategy to reduce off-target effects, its 
effectiveness tend to be overestimated [123]. Since the primary mode of accumulation is passive 
extravasation based on EPR effect, tumor localization does not increase by addition of ligands 
that bind to cancer cells [124, 125]. Nevertheless, one major difference is that cellular uptake 
within tumors are improved with active targeting, as described by the folate and Tf systems 
mentioned [76, 122, 126]. This makes active targeting systems particularly attractive for 
intracellular delivery of therapeutics that are unable to enter cancer cells such as nucleic acids or 
proteins. For instance, Tf coated nanoparticles carrying siRNA (CALAA-01) for cancer 
treatment have been undergoing Phase I of clinical trials for solid tumors [127, 128].  
Considerable research in the field of nanoparticle carriers has provided us with many 
useful insights on designing parameters for ideal anticancer drug carriers. Despite the progress in 
anticancer drug delivery, the use of carriers clinically for cancer therapy has been met with 
limited success thus far. The issues with the existing carriers will be revealed in the next section 




1.4. Issues with Existing Anticancer Drug Carriers  
1.4.1. Delivery of the conventional small molecule anticancer drugs 
 In the area of small molecular hydrophobic drugs for chemotherapy, drug delivery 
systems provided many advantages such as increase in solubility, protection from hostile 
conditions and enzymatic degradation, and most importantly improvements in pharmacokinetics 
and biodistribution profile. Thus it is no surprise that over the past twenty years, many 
formulations entered clinical trials and several were successful in getting FDA approval for 
cancer treatment [115].  
1.4.1.1. Existing carrier formulations and issues 
Some of the carriers that have been approved for clinical use in cancer therapy are listed 
in Table 1-3. Most of the formulations are liposomal nanoparticles with particle size of ~ 100 nm 
with extended blood circulation time. Human trials using DOXIL® revealed that the plasma half-
life was increased from 0.2 hours to 55 hours and AUC was enhanced 300-fold compared to free 
drug [129]. It was accompanied by a 4 to 16-fold enhancement of drug accumulation in 
malignant effusions. So far in clinical settings, these carriers have managed to attenuate the 
toxicity of the free drug and improved patient outcomes.  
However, there are still some concerns with existing systems such as carrier stability and 
drug loading capacity. Table 1-3 describes some of the undesirable side effects associated with 
free drug toxicity for current formulations. Even though polymer drug carriers help to reduce the 
systemic cytotoxicity of chemotherapeutic drugs administered, low stability of the carrier 
formulation in circulation often results in leakage of drugs and extravasation of drugs in healthy 
tissues [51, 130]. In the in vivo environment, the presence of serum proteins induces instability of 
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carriers, possibly due to a variety of mechanisms including protein adsorption, protein 
penetration and drug extraction [131]. Therefore the carriers become ineffective because they 
may be either disintegrated or emptied of its payload by the time they reach the tumor tissue, 
thereby resulting in no efficacy. In addition, drugs that are leaked from carriers while in 
circulation also cause undesirable side effects as they are toxic toward healthy normal cells. 
Conjugation of drug to the polymer itself can improve the stability of the formulation but this 
often comes at the expense of difficulty in drug release at the target site [132]. 
Table 1-4. Commercially available carrier formulations for anticancer drugs. 
Commercial 
Carrier 





















































































Loading capacity refers to the weight percentage of drug payload in the formulation. 
Conventional polymeric carriers are designed improve the typical hydrophobic anticancer drugs’ 
solubility in water, which is derived from hydrophobic interaction between hydrophobic polymer 
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blocks and drugs [137]. Often high molecular weight hydrophobic polymer units are used for the 
purpose. As such, the loading capacity of conventional polymeric micelle system is ~ 10 – 20 % 
(wt/wt) [78], and the commercial liposomal formulations are around 10 % (Table 1-3). The low 
drug loading capacity of polymer system compromises the efficiency of formulations, resulting 
in repeated injections or high dosages. Furthermore, it poses a problem when they are 
administered in vivo, as a large amount of polymers are required to deliver active drug molecules 
sufficient to antitumor activity. Although most polymers used for biomedical applications are 
biocompatible and non-toxic (certified by FDA), the effects of a large amount of polymers on the 
long-term side effects are not understood completely [138]. Even from the clinical point of view, 
it is predicted that the buildup of polymers in the body may lead to unfavorable host response. In 
particular, it was found that the prevalent usage of the polymer PEG has triggered immunogenic 
responses in some patients leading to production of anti-PEG immunoglobulin antibody (anti-
PEG IgM) [139, 140]. Therefore, it is desirable to increase loading capacity of carrier 
formulations and improve carrier stability to achieve higher delivery efficiency as well as 
minimize potential toxicity.  
1.4.1.2. Polymeric micelles for Doxorubicin  
At the research level, many polymeric complexes have been studied for drug delivery to 
tumor tissue. Among them, polymeric micelles are considered a major class of promising 
delivery agents. Table 1-4 summarizes the various polymeric micelle formulations carrying the 
hydrophobic drug Dox. To encapsulate a hydrophobic molecule such as Dox, it is necessary to 
design block copolymers with adequate hydrophobicity. Therefore many micelle carriers that 
were developed tend to incorporate high molecular weight hydrophobic polymers to interact with 
Dox, hence decreasing the weight percentage of the drug in the carrier system considerably [141, 
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142]. Table 1-4 displays the loading capacity of typical Dox micelles developed by other 
researchers, which ranges from 3 – 20 %. This indicates that a large proportion of the mass of the 
formulation is made up of polymer (80 – 90 %). In addition, it was predicted that stability of the 
polymeric micelles could be improved with stronger drug-carrier interactions [143-145]. Thus it 
is possible that while trying to enhance the stability of polymeric micelles, the sizes of the 
hydrophobic portion is increased and as a result drug loading content is decreased. 
Despite the improvement in antitumor efficacy of various Dox loaded polymeric micelles 
formulations (Table 1-4) over free Dox due to more favorable pharmacokinetics and 
biodistribution, little success has been seen in their advancement clinically [78, 79]. One possible 
issue with the drug loaded polymeric micelles is that the encapsulated drug leaks out from the 
carriers while circulating in the bloodstream, either by dilution effect or interaction with 
surfactant proteins in blood [145-147]. Chen et al. demonstrated that a polymeric micelle made 
of  PEG-poly(D,L-lactic acid) (PEG-PDLLA) released its hydrophobic drugs 15 minutes after 
intravenous injection due to interaction with blood components [147]. Another preclinical trials 
of a particular type of block copolymer micelle comprising PEG (Mw 5,000) and polyaspartic 
acid (about 30 units) was found to be unstable after dilution in buffer and resulted in rapid 
release of drugs [148]. To improve the stability, the group modified the polymer backbone such 
that the drug was covalently conjugated to the carrier via a pH-sensitive hydrazone linker. Since 
tumor tissues have a slightly acidic pH [149, 150] compared to normal tissues, acid-degradable 
drug-polymer linkages can be employed to trigger drug release. The pH-responsive micelles 
were stable at physiological pH 7.4 but released increasingly more drugs with lower pH and 
achieved almost 100 % drugs release at pH 3 at 48 hours [151]. With this modification, the 
micelles exhibited tumor inhibition and 4-fold increase in maximum tolerated dosage compared 
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to free Dox (40 mg/kg vs. 10 mg/kg Dox concentration). Therefore the stability of polymeric 





Table 1-5. Polymeric micelles developed for Dox delivery and their characterizations. 
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1.4.2. Intracellular delivery of protein and DNA for cancer 
As mentioned in the previous section, DNAs, siRNAs, and recombinant proteins 
constitute a major new therapeutic modality for chemotherapy. For the delivery of these 
anticancer therapeutics, more attention is needed to address the obstacles at the intracellular level 
since many of such drugs are focused targeting the apoptotic pathways within the cells. Pro-
apoptotic proteins such as caspase-3 [42, 156] and Granzyme B (GzmB) [156, 157]; and p53 
gene [158, 159] which suppresses tumor growth are some prominent examples. To reach the 
targets within the cell, various barriers have to be overcome in the process, including the 
extracellular milieu that comprising various proteases and macrophages, cell membrane and 
endosomal membrane. The protein drug carriers therefore have to secure the passage the protein 
into the cytosol, circumventing all the barriers while maintaining the functionality of the protein 
[160, 161]. For delivery of genes, in addition to all these aforementioned barriers, there is an 
additional obstacle of the nuclear membrane. Intact DNA has to be deposited in the nucleus 
where it exerts its biological function [162, 163].   
1.4.2.1. Existing carrier formulations for intracellular delivery 
Table 1-5 summarizes some of the intracellular delivery agents that have been developed 
for both DNAs and proteins, including polycations, liposomes and cell penetrating peptides. 
However, none of them have been clinically approved at the moment. Many of these vehicles 
demonstrated some efficacy in vitro or even in vivo but still many problems remained.  
Delivery of DNA using non-viral polymers has been examined extensively. Branched and 
linear PEIs are two cationic polymers routinely used for gene transfection in vitro [164, 165]. 
Unfortunately its high charge density and non-biodegradability often resulted in fairly high 
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toxicity, rendering it incompatible with clinical applications [163, 166]. For protein delivery, it is 
important to account for the characteristics of the protein of interest, including charge, molecular 
weight and hydrophobicity and then tailor the design of carrier to accommodate it. Many carriers 
intended for intracellular delivery of payload were positively charged to support adhesion to the 
negatively charged cell membrane before internalization [167, 168]. Although this feature 
facilitated the delivery of negatively charged proteins such as bovine serum albumin (BSA) as 
they can form complexes by electrostatic interaction, it becomes a challenge to deliver positively 
charged proteins. For instance, while several positively charged carriers such as pep-1 and 
Pulsin® was able to bind to negatively charged protein and transport them across the cell 
membrane into the cytoplasm [169-171]; only the liposomal carrier Bioporter® was reported to 
achieve delivery of positively charged proteins such as GzmB [156].  
In addition to designing suitable carriers for different proteins, the stability of protein 
carrier complexes should also be considered. As physical interactions such as electrostatic or 
hydrophobic interactions play a dominant role in carrier-protein interactions, the strength of such 
interactions are easily affected by the environment. Presence of negatively charged serum 
albumin or other proteins can easily weaken the interactions and cause dissociation of the 
complex [172, 173]. Thus many of the carriers become unstable when exposed to external 
conditions, especially in the complex in vivo environment.  
Lastly, the intracellular uptake of these nanoparticle complexes is based solely on affinity 
for cell membrane and not specific to any cell types [160, 172]. If the goal is to deliver a 
cytotoxic cargo to kill a specific group of cells e.g. cancer cells, it would be necessary for the 
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1.4.2.2. Polymeric complexes for protein and DNA delivery  
Table 1-6 summarizes a variety of polymeric complexes used for intracellular protein and 
gene delivery. The two dominant types of non-covalent complexes here are based on electrostatic 
and hydrophobic interactions. In the former category are positively charged polymers such as 
PEI and lipopolyamine that depend on ionic interactions between the negatively charged 
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proteins/DNA with the carrier. To overcome the limitations of anionic cargo, Lee et al. 
developed charge-conversion polyionic complex (PIC) micelles [176]. In PIC micelles, the ε-
amino group on lysine of positively charged Cyt C was modified with citraconic acid or cis-
aconitic acid to turn Cyt C negatively charged so that it could complex with the positively 
charged block copolymer – PEG-poly[N-{N’-(2-aminoethyl)-2-aminoethyl}aspartamide] (PEG–
pAsp(DET)). This modification generated acid-labile amide bonds that could be cleaved in 
acidic endosomal compartment upon endocytosis. After cleavage, the lysine group was restored 
and the protein was then released into the cytoplasm via electrostatic repulsion with the polymer 
PEG-pAsp(DET). 
Complexes based on hydrophobic interactions are also commonly used. Ayame et al. 
developed polymeric nanogels comprising linear polysaccharide pullulan backbone 
functionalized with the hydrophobic cholesterol groups [69]. These cholesterol-bearing pullulan 
(CHP) polymer and protein self-assemble in water by physical crosslinking between the 
hydrophobic cholesterol moieties to form < 50 nm cationic nanogels [69, 71]. CHP nanogels 
complexes containing BSA and β-galactosidase (β-gal) were internalized into cells more 
efficiently than cationic liposomes and protein transduction domains (PTD); and endosomal 
escape of the proteins was also observed 18 hours after treatment.  
To improve the stability of non-covalent complexes, complexes comprising of more than 
one kind of interaction were explored. Jong et al. designed a heparin-Pluronic nanogel system in 
which the negatively charged heparin can bind with positively charged proteins while the 
hydrophobic blocks of Pluronic create a hydrophobic core to retain hydrophobic molecules 
[177]. Using RNase A, they achieved a loading efficiency of > 78 % and demonstrated its 
delivery to the cytoplasm and even nucleus.  
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But stability can also be a double-edged sword. While high stability is desirable during 
cargo transport, the drawback is the difficulty in payload deposit at the target site. Once the 
complex enters the cell; the protein/DNA cargo has to be released in order to exert their 
biological functions. In fact, complexes that are found to be too stable cause a loss of delivery 
efficiency [178-180]. For example, Sato et al. observed that DNA/polygalactosamine (pGalN) 
formed highly stable complexes that were able enter cells but failed to dissociate and led to no 
transfection efficacy [179]. Therefore it is important to control the strength of physical 
interactions by optimizing the ratio of carrier in non-covalent complexes. 
To deliver payload into designated cells, active targeting strategies were explored. One 
approach was to exploit integrin receptor-mediated endocytosis. The tripeptide Arg-Gly-Asp 
(RGD) motif is widely used for targeting integrins such as avb3 and avb5 overexpressed in many 
cancer cells [181, 182]. Using RGD-modified CHP nanogels, Shimoda et al. achieved 
significantly higher (10 times fluorescent intensity using FITC-BSA) delivery of proteins into 
cells than unmodified CHP [71]. Modification of heparin-Pluronic nanogels with RGD-ligand 
was also shown to increase the uptake of complexes into cells as compared to non-modified 
nanogels [183]. These two studies highlighted the possibility of chemical modification of 





Table 1-7. Representative non-covalent complexes for intracellular delivery of proteins and DNA. 
 Type of Complex Polymer Cargo 
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Lipopolyamine DOGS BSA, 
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High efficiency comparable to commercial 
agents  
Binds negatively charged proteins only  
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Nano-sized carriers for passive targeting 
Non-toxic 
 
RGD peptide active targeting 
Redox responsive for intracellular release 
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1.5. Drug carrier design based on (-)-Epigallocatechin-3-gallate (EGCG) 
1.5.1. EGCG Overview 
(-)-Epigallocatechin-3-gallate (EGCG) is the major component of green tea catechins and 
is well-known for its anti-oxidative, anti-mutagenic, anti-inflammatory and anti-carcinogenic 
properties [194-196]. EGCG is a small molecule compound with a Mw of 458 g/mol and its 
chemical structural comprises of 3 phenol rings and another 6-membered ring with many 
hydroxyl functional groups (Figure 1-5). This structure of EGCG confers it with the ability to 
engage in a multitude of non-covalent interactions with other molecules such as hydrophobic 
interaction [197-200], hydrogen bonding [197-200] and π-π stacking [201, 202] interactions. In 
particular, EGCG has been shown to bind with bioactive macromolecules such as proteins – 
lysozyme [197] and human serum albumin (HSA) [199, 200] through both hydrophobic 
interactions and hydrogen bonding. In light of this property of EGCG, integrating EGCG moiety 
as part of drug carriers for anticancer therapeutics could potentially lead to augmented 
interaction between the carrier and payload and address some of the shortcomings of the DDS 














Figure 1-5. Chemical structure of (-)-epigallocatechin-3-gallate (EGCG). 
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1.5.2. EGCG as a component of drug carriers  
The motivation for using EGCG in carrier design is the ability of EGCG to interact with a 
wide variety of therapeutic molecules such as small molecule drug, DNA or protein through 
physical interactions. It is expected that such favorable interactions with drugs/proteins/DNA 
would lead to formation of stable complexes with higher loading capacity.   
The goal therefore is to develop polymeric carriers based on EGCG for cancer therapy. 
Two types of non-covalent polymeric complexes in which EGCG can be incorporated are 
polymeric micelles and nanogels. An approach to prepare polymeric micelles involves 
conjugation of EGCG moieties onto the terminal end of hydrophilic polymer blocks. The 
resultant amphiphilic conjugate can potentially self-assemble to form micelles with hydrophobic 
anticancer drugs encapsulated within the EGCG core. On the other hand, a nanogel can be 
formed by physical or chemical interactions between EGCG moieties grafted onto side groups of 
linear polymers. Various therapeutics can potentially be entrapped within the nanogel complex 
by physical interactions. 
                              
                                         

























To this end, two different EGCG based conjugates were developed - PEG-EGCG 
conjugate (polymeric micelle system) and hyaluronic acid (HA)-EGCG conjugate (HA-EGCG) 
(nanogel system) (Figure 1-6). These two different polymeric carriers were designed specifically 
to tackle the challenges associated with drug delivery to tumor and intracellular delivery of 
protein and DNA respectively.  
1.5.3. PEG-EGCG carrier for Dox delivery 
                                    
Figure 1-7. Structural similarity of EGCG and Dox, both comprising of multiple rings. 
PEG-EGCG conjugate was designed to form polymeric micelles for the delivery of small 
molecular drugs to tumor tissues. Dox is chosen as the anticancer drug. Dox is an anthracycline 
antibiotic widely used for chemotherapy. It is a topoisomerase II inhibitor and it 
hinders DNA synthesis and replication by intercalating between base pairs of the DNA strand 
[25, 203]. Because of its high potency and non-selectivity, severe side effects are common, 
including cardiomyopathy and congestive heart failure [204, 205]. Thus many carrier 
formulations for Dox were developed but with limited success [206].  
Among the issues related to Dox delivery systems, the two that are emphasized in this 
thesis are drug loading capacity and stability. In the section 1.4.1.2., it is suggested that the 
interaction between Dox and the carrier is an important factor in determining loading capacity 
Dox  EGCG 
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and stability. Thus it is postulated that EGCG moiety could be used to enhance interactions and 
facilitate Dox delivery. Figure 1-7 depicts the chemical structures of EGCG and the small 
molecular anticancer drug Dox which both share similar multiple rings. This similarity in 
structure could lead to favorable intermolecular interactions between the two compounds, in 
particular π-π stacking and hydrophobic interactions. Therefore EGCG was chosen as the 
component of the inner core of a polymeric micelle that interacts with Dox. The corona 
hydrophilic component composes of PEG chains that provide both solubility and “Stealth” 
property.  With this EGCG core and PEG corona arrangement, PEG-EGCG conjugates and DOX 
would then self-assemble in aqueous environment to form Dox encapsulated micelles.  
In contrast to other block copolymers listed in Table 1-4, instead of having a long-
chained hydrophobic polymer block such as poly(ε-caprolactone) (PCL) or poly(b-benzyl-l-
aspartate) (PBLA), EGCG moiety with a Mw of 458 g/mol, would be able to interact with Dox 
efficiently. This would drastically reduce the amount of polymeric carrier used and in turn the 
proportion of polymer in the drug formulation. Accordingly, the drug loading capacity can be 
significantly improved. In sum, as a result of the favorable physical interactions between EGCG 
and Dox in the hydrophobic core, PEG-EGCG polymeric micelles encapsulating Dox is expected 
to have high drug loading capacity and stability. Thus chemotherapy using stable Dox-loaded 
PEG-EGCG nanoparticle micelles could overcome the problem of carrier dissociation and drug 
leakage in circulation, thereby potentially reduce side effects and improve anticancer efficacy.  
1.5.4. HA-EGCG carrier for intracellular delivery 
HA-EGCG conjugate was designed for the targeted intracellular delivery of protein and 
DNA in the form of nanogel complexes. Two issues associated with delivery of intracellular 
anticancer therapeutics such as proteins and DNA to cancer cells are instability and non-
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specificity. In the formation of non-covalent complexes, stability is dependent on the interactions 
between the carrier and the cargo. Since EGCG has the ability to bind both protein and DNA 
efficiently through hydrophobic interactions, hydrogen bonding and π-π stacking [197, 199, 200, 
202, 207], it would be ideal to leverage on this property in designing polymeric carriers for 
protein delivery. It is expected that the physical interactions between EGCG and proteins/DNA 
would lead to more stable complex formation and enhance the delivery efficacy.  
To improve cancer cell targeting, EGCG moieties were grafted onto hyaluronic acid 
(HA) polymer backbone. HA is a linear polysaccharide composed of N-acetylglucosamine and 
glucuronic acid disaccharide repeats of variable length [208, 209]. HA plays an important role in 
cancer biology and it is believed to be involved in biological functions related to cell 
proliferation, motility, angiogenesis and malignancy [209-212]. More importantly, it binds to 
HA-receptor, CD44 that are expressed abundantly on many types of cancer cells and enables the 
uptake of HA by CD44-mediated endocytosis [213, 214]. The application of HA to target cancer 
cells have been demonstrated extensively [215, 216]. 
In addition, cancer stem cells, which are a small group of tumor initiating cells within the 
tumor mass, also display elevated levels of CD44 receptors. Cancer stem cells (CSCs) have been 
recognized as important targets for cancer treatment because they are closely associated with 
proliferation and metastasis of cancer cells, as well as enhanced drug resistance and tumor 
relapse rate [217, 218]. Conventional chemotherapy that eliminates rapidly proliferative cells has 
little effect on these cells because CSCs are believed to be in a dormant state [219, 220]. By 
virtue of CD44 targeting, HA based therapeutics could potentially deliver anticancer therapeutics 
selectively to CSCs to achieve complete cancer eradication. 
41 
 
By grafting EGCG moiety onto the HA polymer backbone, we hypothesized that EGCG 
and protein/DNA interaction would serve as a driving force for the self-assembly of stable 
nanogel complexes. The resultant HA-EGCG nanogel complexes would be useful for CD44 
targeting by specific delivery of anticancer therapeutics to cancer cells. Since CD44 is also a 
biomarker of CSCs, this nanogel system can potentially target CSCs to achieve more effective 







Our research focusses on using a novel compound - green tea catechin, EGCG as an 
ingredient of polymeric carriers for cancer therapy. EGCG has been shown to interact with a 
variety of bioactive molecules including proteins, DNA and small molecular drugs. Therefore we 
hypothesize that EGCG moiety can be leveraged in carrier design to deliver multiple therapeutic 
payloads (Figure 1-8).   
 
Figure 1-8. Design of EGCG based polymeric carriers for delivery of various anticancer therapeutics. 
Hence, the overall objective is to develop polymeric carriers for the delivery of various 
cancer therapeutics based on EGCG. For this purpose, we synthesized two different EGCG based 
conjugates - PEG-EGCG and HA-EGCG; and explored the possibility of using them for the 
delivery of three types of cargo – small molecule drug Dox, protein and DNA. The specific aims 
within each of the three sections are outlined below:  
• Delivery of Dox to tumor tissue using PEG-EGCG conjugates 
– Physically encapsulate Dox into PEG-EGCG polymeric micelles   
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– Prepare Dox-loaded PEG-EGCG micelles of high drug loading capacity and 
high stability 
– Achieve significant antitumor efficacy using Dox-loaded PEG-EGCG 
micelles in vivo with little unwanted toxicity 
• Intracellular delivery of protein by HA-EGCG conjugates 
– Investigate interactions between EGCG and the protein GzmB and form stable 
GzmB and HA-EGCG nanogel complexes 
– Demonstrate selective killing of CD44 overexpressing cancer cells by using 
the nanogel complexes to deliver GzmB into cytosol of those cells via CD44-
mediated endocytosis 
• Gene delivery by HA-EGCG conjugates 
– Prepare and characterize HA-EGCG/PEI/DNA nanogel complexes for gene 
delivery 
– Improve transfection efficiency of CD44 overexpressing cancer cells by 
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Chapter 2: Development of doxorubicin-loaded 
poly(ethylene glycol)-green tea catechin 





Chemotherapy has been widely used for cancer treatment but is plagued by rampant 
toxicity [1]. Chemotherapeutic drugs damage all proliferating cells in the body non-specifically 
in hope that cancer cells are eliminated before normal cells [2, 3]. In addition, majority of the 
administered drugs do not reach their intended target tumors but are distributed throughout other 
parts of the body instead, contributing to adverse side effects such as nausea, hemorrhage and 
inflammation. The application of nanomedicine, in particular anticancer drug delivery systems, 
has been widely considered as a promising strategy to improve conventional chemotherapy [4]. 
Anticancer drugs packaged in nanoparticle formulations experienced drastically improved 
pharmacokinetics and tissue distribution over the stand-alone drug [5, 6], resulting in diminished 
toxicity. This has led to the eventual approval of liposomal nanocarriers such as DOXIL® for 
clinical use [7].  
One class of nanocarriers that has garnered increasing interest is polymeric micelle. 
Polymeric micelles are well-defined core-shell structures consisting of a hydrophobic inner core 
for drug loading and a hydrophilic shell - typically comprising linear PEG that provides the 
“Stealth” property in circulation [8]. Micellar carriers confer several advantages, such as 
increased drug solubility, increased plasma half-life and reduced clearance by reticulo-
endothelial system (RES) [8, 9]. In addition, their nanosizes (~ 100 nm) allow them to 
accumulate passively at tumor site via enhanced permeability and retention (EPR) effect [10]. 
One of the most successful micelle formulations for the delivery of various anticancer drugs 
developed by Kataoka et al., based on the PEG-poly(aspartic acid) block copolymer, has since 
progressed to the clinical stages [11]. Despite the promises, several concerns still remain. First, 
typical polymer micelles have low drug loading capacities of 5 – 20 % (w/w) [8, 12] because 
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they generally encompass high molecular weight hydrophobic polymer units to interact 
favorably with hydrophobic drugs, leading to low drug loading and low carrier efficiency [13]. 
Second, upon intravenous administration polymeric micelles are confronted by many challenges 
in the blood stream that may disrupt their integrity [14, 15]. For instance, severe dilution to 
below the critical micelle concentration (CMC) may lead to dissociation of micelles [16]. In 
addition, they may be destabilized by blood plasma proteins through adsorption and core 
infiltration, leading to premature release of drugs [17, 18]. This instability not only hamper the 
delivery of anticancer drugs to tumor sites but may also lead to off-target toxicity [15, 19].     
In our efforts to design micellar carriers to overcome these limitations, we are inspired to 
incorporate the molecule EGCG as a novel feature. EGCG is the main constituent of green tea 
catechins that is widely reported to possess anticancer and anti-oxidative properties [20, 21]. Dox 
is chosen as the anticancer drug. Dox is an anthracycline antibiotic widely used for 
chemotherapy. It is a topoisomerase II inhibitor and hinders DNA synthesis and replication by 
intercalating between base pairs of the DNA strand [22]. Both EGCG and Dox are small 
molecules and share similar aromatic multiple-ringed chemical structures. Based on reports of 
EGCG binding to aromatic residues of proteins through π-π stacking and hydrophobic 
interactions [23, 24], we expect that this similarity in structure could lead to favorable 
intermolecular interactions between the two molecules. 
 In this chapter, the formation of a novel polymeric anticancer drug carrier, Dox-loaded 
EGCG based micelle is described. PEG-EGCG conjugates - comprising two EGCG moieties 
chemically bonded to the terminal end of PEG chain, were synthesized and used to prepare Dox 
encapsulating micelles. We hypothesize that interactions between EGCG and Dox would support 
the formation of a core-shell micellar configuration in which EGCG and Dox could be 
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sequestered in the hydrophobic core surrounded by a hydrophilic PEG shell. As a result of the 
strong interactions between EGCG and Dox, these Dox-loaded PEG-EGCG micelles are 
expected to have enhanced drug loading capacity and stability. Hence, we investigated the 
physicochemical properties of the Dox-loaded PEG-EGCG micelles including size, drug loading 
capacity, drug release profile and stability. Most importantly, the anticancer effects of the Dox-
loaded PEG-EGCG micelles were evaluated in HAK-1B liver carcinoma cells both in vitro and 
in vivo, with two clinically relevant Dox formulations - free Dox and the nanocarrier based 
DOXIL® as comparisons.  
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2.2. Materials and Methods 
2.2.1. Materials 
Dox·HCl was purchased from (Boryung Pharm. Inc, Korea). PEG-aldehyde (PEG-CHO) was 
bought from NOF Japan. EGCG (TEAVIGO) was purchased from DMS Nutritional Products 
Ltd Switzerland. AlamarBlue® was purchased from Invitrogen. All buffers, including phosphate 
buffer saline ((PBS) 150 mM, pH 7.3), and media were supplied by Biopolis Shared Facilities 
(BSF), Singapore. 
2.2.2. Synthesis of PEG-EGCG Conjugate 
PEG-EGCG was synthesized by conjugation between a terminal aldehyde group of PEG-
CHO and the A ring of EGCG as described in a previous report [25]. Briefly, the aldehyde-
terminated PEG (PEG-CHO, Mw 5000) and EGCG were separately dissolved in a mixture of 
acetic acid, water and DMSO. The reaction was initiated with the dropwise addition of the PEG-
CHO solution, and was conducted at 20 °C (pH 2) under a nitrogen atmosphere for 48 h. The 
resulting products were dialyzed (Mw cut-off: 3500 Da) and lyophilized to give PEG-EGCG. 
2.2.3. Preparation of Dox-loaded PEG-EGCG micelles 
Dox·HCl was dissolved in 1 ml of DMF at final concentration of 12 mg/ml. Five mole 
ratio of TEA was added to the solution and the mixture was vortexed for 15 min. Subsequently, 6 
different concentrations of PEG-EGCG (Mw 5,000) in the range of 0.5 - 24 mg/ml pre-dissolved 
in 1 ml of DMF were added and the final mixture was vortexed for another 1 h at room 
temperature. Following that, the mixtures were transferred into dialysis tubings (Mw cut-off: 
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3500 Da) (Spectrapor, Spectrumlabs, USA) and dialyzed against de-ionized water. Water was 
changed every 6 - 8 h. After 3 days of dialysis, the contents from the dialysis tubings were 
collected and freeze-dried.  
An optimized batch of highly concentrated Dox-loaded PEG-EGCG micelles which 
comprised PEG-EGCG (Mw 10,000) (10kPE-1U) was also prepared. Both feed Dox and PEG-
EGCG concentrations were lowered to 1 mg/ml by dissolving in 12 ml of DMF. After mixing, 
dialysis was performed for 6 h and then the contents from tubing were subjected to ultrafiltration 
using Amicon Ultra-15 centrifugal filter units (Millipore) to remove the free Dox from the 
micelle solution. The sample was then freeze-dried.  
2.2.4. Determination of physiochemical properties of micelles 
1. NMR  
Freeze-dried Dox-loaded PEG-EGCG micelles were dissolved in D2O or DMSO-d6 for 
NMR analysis. Proton NMR signals were recorded with a Bruker 400 MHz Ultrashield Plus 
(Bruker BioSpin, MA, USA) and chemical shifts were expressed as parts per million (ppm). 
2. Particle size  
Dynamic light scattering (DLS) was used to determine the hydrodynamic size of the 
Dox-loaded PEG-EGCG micelles. The micelle solutions were passed through 0.2 µm microfilter 
before measurement. DLS measurements were performed using Zetasizer 3000 HAS (Malvern 
Instrument Ltd., Malvern, UK) equipped with a He–Ne laser beam at 658 nm (dynamic light 





3. Drug loading  
Freeze-dried micelles were re-dissolved in DMF for quantification of drug loading. The 
amount of Dox in the micelle was determined by measuring the absorbance at 480 nm using a 
UV–VIS spectrophotometer (Hitachi). Dox solutions of various concentrations in DMF were 
prepared, and the absorbance at 485 nm was measured to generate a standard curve to determine 
concentration of Dox in micelle samples. After obtaining the Dox amount in micelle, drug 
loading content (DLC) and drug loading efficiency (DLE) could be derived using formula 1 and 
formula 2 respectively.  
100
micelle of weight total
micellein  drug ofweight (%) (DLC)content  loading Drug ×=  
 
100
feedin  drug ofweight 
micellein  drug ofweight (%) (DLE) efficiency loading Drug ×=
 
4. Fluorescence intensity  
 Dox-loaded PEG-EGCG micelles were diluted in water to final Dox concentration of 
200 µg/ml as determined by absorbance measurements. The micelles were then subjected to 
fluorescence measurements using a FluoroMax-4 spectrofluorometer (Horiba). The excitation 
wavelength was fixed at 480 nm and the emission wavelength range of 520 – 650 nm was 
monitored. Free Dox was used as control in both experimental settings.   
5. Critical micelle concentration (CMC) 
CMC was determined by dynamic laser scattering (DLS) using the Malvern Zetasizer, 
using a method described previously [26]. Detection was made using back scatter optical 
arrangement at an angle of 173°. A series of micelle solutions ranging from 2 to 0.05 µg/ml was 
prepared from an aqueous stock solution of Dox-loaded PEG-EGCG micelle. Hydrodynamic size 





points correspond to the estimated CMC value of the micelle. All the measurements were 
performed in triplicates. 
6. Kinetic stability  
The kinetic stability of the Dox-loaded PEG-EGCG micelles was probed by two 
independent methods. The first method is to monitor the change in the hydrodynamic size of 
micelle caused by fetal bovine serum (FBS) destabilization. The micelles were diluted in PBS 
with 10 % FBS to reach a final concentration of 250 µg/ml and the sizes of the micelles were 
monitored up to 4 weeks.  
In the second method, the scattered light intensity of the micelles in distilled water was 
measured in the presence of sodium dodecyl sulfate (SDS) acting as a destabilizing agent. Thirty 
µl of SDS solution (50 mg/ml) was added to 1 ml of the micelles (250 µg/ml) and the scattered 
light intensity of the resultant solution was monitored by DLS over a period of up to 4 weeks. All 
the measurements were performed in triplicates. 
2.2.5. In vitro release study  
Freeze-dried micelle samples were re-suspended in water and transferred into dialysis 
tubings (Mw cut-off: 1000 Da). Sample Dox concentrations were fixed at 200 μg/ml. The tubing 
was placed into 30 ml PBS solutions in a 50-ml centrifuge tube. The release of Dox was 
monitored at 37 oC in an incubator shaker. At selected time intervals, buffered solution outside 
the dialysis bag was removed for fluorescence measurements (Hitachi Spectroflurometer F-2500) 
and replaced with fresh buffer solution. A Dox standard curve at fluorescence intensity of 480 
nm was generated and the Dox sample concentrations were calculated based on it.  
2.2.6. Cell viability assay 
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HepG2 hepatocarcinoma cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) and HAK-1B liver carcinoma cells were maintained in RPMI medium 1640, both 
containing 10 % FBS and 1 % penicillin/streptomycin at 37 °C with 5 % CO2. For cytotoxicity 
assay, both cells were harvested and plated at a density of 10,000 cells per well in 96-well plates 
and incubated for 24 h. Cells were then exposed to a series of free Dox or micelle-encapsulated 
Dox at various concentrations for a designated period of time. The viability of cells was 
determined using the AlamarBlue® assay (Invitrogen) at the designated time-points. Briefly, cells 
were gently washed with PBS once before fresh medium with AlamarBlue® (10 % v/v) was 
added. The cells were incubated for another 2 h and fluorescence was measured using a Tecan 
Infinite Microplate Reader (Ex/Em: 545/590 nm). Cell viability was expressed as a percentage of 
untreated control cells and the data was reported as mean ± s.d. of quadruplicates. 
2.2.7. Intracellular trafficking of DOX-loaded PEG-EGCG micelle 
HAK-1B cells were seeded in an 8-well chamber slide (Lab-Tek®) and left to attach 
overnight. Free Dox (25 µg/ml) and Dox-loaded PEG-EGCG micelles (25 µg/ml of Dox 
equivalent concentration) were added to the cells and incubated for 4 or 24 h. Before confocal 
microscopy, cells were gently washed twice with cold PBS and the cell nuclei were subsequently 
stained with Hoechst 33342 (Molecular Probes). Finally, the cells were visualized using a 
confocal laser scanning microscope (Zeiss LSM 510 META).  
2.2.8. In vivo tumor inhibition study  
 The in vivo study was performed on 6 – 8 weeks old BALB/c nude mice using a HAK-1B 
human liver carcinoma xenograft model. To establish the HAK-1B model, the mice were 
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injected subcutaneously in the right flank with 0.1 ml of cell suspension containing 10 million 
HAK-1B cells. When the tumors had grown to approximately 100 mm3, the various treatments 
were administered (day 0). Tumor-bearing mice were randomly assigned to one of the following 
treatment groups (n = 8 - 10 mice per group): normal saline (control), free Dox: 1 mg/kg, 2 
mg/kg, 5 mg/kg and 10 mg/kg, DOXIL: 1 mg/kg, 2 mg/kg, 5 mg/kg and 10 mg/kg and Dox-
loaded PEG-EGCG micelles: 25 mg/kg and 50 mg/kg. All dosages were reported as Dox 
equivalent concentrations. Three dosages of various treatments were given through tail vein 
injection on day 0, day 4 and day 7 respectively. The tumor size and body weight of all the 
tumor-bearing mice were monitored. The tumor size was measured externally using calipers 
during the experimental period and was approximated by using the equation vol. = (a × b2)/2, 
where vol is volume, a is the length of the major axis, and b is the length of the minor axis. The 
C-26 mouse colon carcinoma model was established in a similar manner. But only 10,000 C-26 
cells were subcutaneously injected per mice. All other treatment procedures except the 
administered samples were consistent with HAK-1B study. All animal studies were performed in 
accordance to protocols approved by the Singapore Biological Resource Centre's Institutional 
Animal Care and Use Committee (IACUC). 
2.2.10. Statistical analysis  
Data were expressed as mean ± s.d. Student's t-test was used for all statistical analysis 
between two groups. ANOVA testing (OriginLab Corporation, MA, USA) of sample means was 




2.3. Results and discussion 
2.3.1. Preparation and characterizations of Dox-loaded PEG-EGCG micelles 
 PEG-EGCG conjugates were synthesized by aldehyde-mediated reaction between A-ring 
of EGCG and aldehyde-terminated PEG, as described in a previous report [25]. In this study, we 
prepared Dox-loaded PEG-EGCG micelles using the dialysis method in which a mixture of Dox 
and PEG-EGCG conjugates in organic solvent was dialyzed against water. Driven by the 
interactions between EGCG moieties and Dox, we hypothesize that PEG-EGCG conjugates and 
Dox would self-assemble spontaneously to form Dox-encapsulated PEG-EGCG micelles (Figure 
2-1).  
 
Figure 2-1. Formation of Dox-encapsulated PEG-EGCG micelles by the self-assembly of Dox and PEG-
EGCG conjugates in aqueous solution.  
We attempted to prepare micelles by varying the feed weight ratio of PEG-EGCG 
conjugates to Dox. The feed Dox concentration was fixed at 12 mg/ml. Six different feed PEG-
EGCG (Mw 5,000) to Dox weight ratios in the range of 0.04 - 2 were used. A control with PEG-
EGCG (0 mg/ml) was also set up. Figure 2-2 illustrates the appearance of the test solutions after 
dialysis. Distinct red Dox precipitate was observed for samples prepared using PEG-EGCG to 
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Dox feed weight ratios below 0.08 (Figure 2-2 a). In contrast, samples with PEG-EGCG to Dox 
feed weight ratios above 0.25 yielded clear homogeneous solutions without any precipitate 
(Figure 2-2 b). It is clear from the results that the solubility of Dox dramatically increased with 
higher PEG-EGCG concentration.  
Figure 2-2. Preparation of PEG-EGCG and Dox micelles using dialysis method. (a) Formation of free Dox 
precipitates in PEG-EGCG (Mw 5,000) to Dox feed weight ratio < 0.08. (b) Clear homogenous solutions were 
obtained at PEG-EGCG to Dox feed weight ratios > 0.25. 
 
 
In accordance with previous report [27], in absence of PEG-EGCG, the hydrophobic Dox 
molecules interacted with one another to form Dox-Dox self-aggregates, leading to precipitation 
in aqueous environment. The formation of Dox self-aggregates was corroborated by the 
observation of self-quenching of Dox fluorescence with increasing Dox concentrations (Figure 
2-3 a). Besides Dox-Dox associations, Dox molecules could also interact with EGCG molecules 
through hydrophobic and π-π stacking interactions, resulting in concentration-dependent 
quenching of Dox fluorescence as shown in Figure 2-3 b. Therefore the solubility data suggests 
that the interactions between Dox and EGCG moieties on PEG-EGCG contributed to the 






Figure 2-3. (a) Self-quenching of Dox fluorescence with increasing Dox concentrations. (b) EGCG induced 
quenching of Dox fluorescence with fixed Dox concentration of 5 µg/ml. 
 
To verify that the interactions between EGCG and Dox led to micelle formation, 1H 
NMR analysis was performed on the sample with PEG-EGCG to Dox feed weight feed ratio of 
0.25 which yielded a clear solution. The sample was freeze-dried and resuspended in two 
solvents - DMSO-d6 and D2O (Figure 2-4). In DMSO-d6, prominent peaks (4.0 - 8.5 ppm) of 
Dox were observed along with the ethylene proton peak of PEG at ~3.6 ppm, indicating that the 
sample contained both PEG and Dox. In contrast, only the peak corresponding to ethylene 
repeating unit of PEG was visible in D2O but not Dox peaks. A possible explanation is that in 
DMSO-d6, both the PEG-EGCG and Dox were fully dissolved in mixture form, thereby 
contributing to 1H NMR signal. However in D2O, they adopted a core-shell conformation in 
which Dox was encapsulated within the core and thus insufficiently solvated to produce a signal. 
Therefore these results indicate the successful encapsulation of Dox by PEG-EGCG conjugates 
to form micelles, which is consistent with other reports of micelle formation based on 1H NMR 
analysis [28, 29]. 
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Figure 2-4. 1H NMR spectrum of Dox-loaded PEG-EGCG micelle in (a) DMSO-d6, in comparison with the 
spectrum observed in (b) D2O.  
 
2.3.2. Characterizations of Dox-loaded PEG-EGCG micelles 
After confirming micelle formation from the characterization above, we investigated the 
physicochemical properties of the micelles. Table 2-1 summarizes the results. The micelles 
prepared with PEG-EGCG (Mw 5,000) to Dox feed weight ratios of 0.25, 0.5, 1 and 2 were 
denoted as 5kPE-0.25, 5kPE-0.5, 5kPE-1 and 5kPE-2 respectively. First, drug loading efficiency 
(DLE) improved with increasing PEG-EGCG to Dox feed weight ratio, since increasing PEG-
EGCG probably resulted in more efficient Dox entrapment. This was supported by finding that 
the solubility of Dox was enhanced with higher PEG-EGCG concentrations. Second, drug 
loading content (DLC) increased with decreasing PEG-EGCG to Dox feed weight ratio. We 
noted that a very low PEG-EGCG to Dox feed weight ratios of 0.25 was sufficient to achieve 
effective Dox encapsulation, which led to an exceptionally high DLC of 5kPE-0.25 micelles at 
86 %. This is significantly higher than the average Dox loading content of 5 - 20 % obtained 
from using other block copolymer micelles [8]. This is probably because existing block 
copolymer micelles tend to incorporate high molecular weight hydrophobic blocks to interact 
with Dox, thus decreasing the weight percentage of the drug in the carrier system considerably. 
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For instance, PEG-poly(b-benzyl-l-aspartate) (PEG-PBLA) micelles that attained a DLC of 20 % 
were formed using block copolymer with molecular weight of ~ 18,000 Da [30]. In contrast, as 
PEG-EGCG conjugate had a much smaller molecular weight of ~ 6,000 Da, the weight 
percentage of Dox in PEG-EGCG micelles was increased significantly. It is worth mentioning 
that a DLC of 86 % indicated that the molar ratio of Dox to EGCG ratio was ~ 30 to 1. To 
achieve this high level of Dox loading, we hypothesize that during dialysis in aqueous 
environment, hydrophobic Dox molecules with interact with each other as well as with EGCG 
moieties. The interaction between Dox and EGCG would drive the self-assembly of core-shell 
nanostructures in the form of micelles. In the process of micelle formation, many Dox molecules, 
including Dox-Dox self-aggregates, were packed into the concentrated hydrophobic core, 
thereby yielding clear solutions (Figure 2-2). While in the absence of PEG-EGCG, Dox-Dox 
self-aggregates precipitated readily. As a result of the effective encapsulation of Dox and Dox-
Dox self-aggregates, an exceptionally high drug loading content was obtained.  
Finally, the particle sizes of all the micelles were determined. As PEG-EGCG to Dox 
feed weight ratio increased from 0.25 to 2, the particle sizes decreased from 93 nm to 21.4 nm. 
The reduction in size as a function of increasing PEG-EGCG to Dox feed weight ratio correlates 
well with DLC. This implies that particle size could be directly influenced by the amount of Dox 
encapsulated within the core of micelle.  
We also prepared another batch of highly concentrated Dox-loaded PEG-EGCG micelles 
using PEG-EGCG (Mw 10,000). A modification was introduced in the preparation protocol for 
this batch - The feed Dox and PEG-EGCG concentrations were lowered to 1 mg/ml.  
The characteristics of this batch of micelles (10kPE) are listed in Table 2-1. The DLEs 
were higher than the 5kPE counterparts while the DLCs were found to be similar to 5kPE 
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micelles. Interestingly, we observed that particle size was considerably larger (124 - 152 nm) 
compared to 5kPE micelles, possibly due to increase in the PEG chain lengths. 10kPE-1 micelles 
were further concentrated by ultrafiltration to increase Dox concentration of the micelle (10kPE-
1U) for in vitro and in vivo studies.  
 
Table 2-1. Characterization of Dox-loaded PEG-EGCG micelle with various PEG-EGCG to Dox feed weight 
ratios and PEG-EGCG molecular weights. 
 
2.3.3. Quenching of Dox fluorescence in PEG-EGCG micelles 
 It has been reported that the π-π stacking of Dox molecules led to the quenching of Dox 
fluorescence encapsulated within polymeric micelles [31, 32]. To investigate the interactions of 
Dox within PEG-EGCG micelles, we examined the fluorescence of Dox in the micelle 
configuration. It could be clearly seen that while the absorbance of Dox at equal concentrations 
was similar in both the free form and the micelle encapsulated form, Dox fluorescence was 
significantly decreased when encapsulated in the 10kPE micelles (Figure 2-5). The quenching of 
Dox fluorescence confirmed the π-π stacking of Dox molecules within the hydrophobic core of 
Samples Feed weight 
ratio of PEG-










5kPE-0.25 0.25 3 57 ± 3.8 86 ± 1.8 96 ± 15 
5kPE-0.5 0.5 6 65 ± 5.6 68 ± 3.7 33 ± 5.1 
5kPE-1 1 12 75 ± 4.0 49 ± 2.2 29 ± 2.6 
5kPE-2 2 24 78 ± 5.9 34 ± 2.2 31 ± 11 
10kPE-0.25 0.25 0.5 77 ± 0.8 88 ± 3.4 152 ± 4.7 
10kPE-0.5 0.5 1 79 ± 4.2 69 ± 2.4 135 ± 4.8 
10kPE-1 1 2 82 ± 4.8 49 ± 1.5 124 ± 5.5 
10kPE-2 2 4 88 ± 4.4 34 ± 1.1 136 ± 8.9 
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PEG-EGCG micelles, which could be attributed to interactions between Dox itself as well as 
Dox and the aromatic EGCG moieties.      
Figure 2-5. (a) Absorbance of free Dox and Dox-loaded 10kPE micelles and (b) fluorescence intensities of free 
Dox and Dox loaded 10kPE micelles at equivalent concentrations. 
 
2.3.4. Stability of Dox-loaded PEG-EGCG micelles 
2.3.4.1. Thermodynamic stability 
Micelle stability is an important consideration for drug delivery application in vivo. The 
two components of stability - thermodynamic and kinetic parameters of Dox-loaded PEG-EGCG 
micelles were assessed. Thermodynamic stability is governed by the critical micelle 
concentration (CMC) of the polymer, which is defined as the concentration below which the 
disassembly of micelle occurs [16]. In other words, a lower CMC value means that micelles are 
more stable. In general, drug-loaded micelles are subjected to severe dilution upon intravenous 
injection. Micelles with high CMCs are more easily destabilized, leading to drug leakage and 
unspecific toxicity. Here the CMC of Dox-loaded PEG-EGCG micelles (10kPE-1U) was 
determined to be 0.15 mg/l (Figure 2-6), which was about 2 orders of magnitude lower than most 
other block copolymer micelles [33, 34]. For instance, PEG-poly(caprolactone) (PCL) micelles 
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and  PEG-polycarbonate micelles were reported to have CMCs of 12 - 20 mg/l [28] and 15 - 63 
mg/l [35] respectively.  
 
Figure 2-6. Evaluation of critical micelle concentration (CMC) of Dox-loaded PEG-EGCG micelles using DLS 
technique. 
 
2.3.4.2. Kinetic stability  
Apart from dilution effect, another concern for micellar carriers is plasma protein 
destabilization. Plasma proteins can partition into core compartment of micelles to trigger 
disassembly [14]. Moreover, adsorption of opsonin proteins on the surface of nanoparticles also 
leads to aggregation and clearance by the reticulo-endothelial system (RES) in the liver and 
spleen [36]. To study the kinetic stability of micelles, the particle size of the 10kPE-1U was 
monitored as a function of time in a simulated physiological environment, i.e. PBS (pH 7.3) 
containing 10 % FBS at 37 ºC. We found no significant change in size observed over a period of 
4 weeks (Figure 2-7 a). This strongly suggests that the 10kPE-1U was highly stable in the 
presence of serum and was effective in preventing protein adsorption and aggregation. 
The kinetic stability of micelles was also probed by DLS in the presence of the surfactant 
sodium dodecyl sulfate (SDS), which acted as a destabilizing agent as described by others [37, 
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38]. Figure 2-7 b shows the time dependence in scattered light intensity of 10kPE-1U. SDS-
treated micelles exhibited a small decrease in scattered light intensity to about 90 % in 1 h. The 
signal then increased to 96 % and was maintained at > 92 % for 48 h, suggesting that there was 
little dissociation of 10kPE-1U. In fact, the scattered light intensity was preserved at > 90 % at 
even after 4 weeks at room temperature. The ability to withstand SDS challenge even after 4 
weeks again confirms the high kinetic stability of micelles. Overall, Dox-loaded PEG-EGCG 
micelles demonstrated excellent thermodynamic and kinetic stability. This could probably be 
attributed to the strong interactions between EGCG and Dox in the micellar core, thus enabling 
the micellar structure to be maintained effectively. The highly stable micelles hold great promise 
for in vivo applications.    
Figure 2-7. Kinetic stability of Dox-loaded PEG-EGCG micelles. (a) The effect of serum on particle size as a 
function of time. (b) The effect of SDS on DLS light intensity as a function of time. 
  
2.3.5. In vitro release profile of Dox-loaded PEG-EGCG micelles  
Drug release is an important parameter in carrier design for both reducing systemic drug 
leakage and achieving therapeutic efficacy. In vitro Dox release from PEG-EGCG micelles was 
investigated. For PEG-EGCG (Mw 5,000) micelles, we found that micelles prepared from all the 
various PEG-EGCG to Dox feed weight ratios released Dox slowly, reaching a cumulative 
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release of 8 - 9 % in 14 days (Figure 2-8 a). For the concentrated Dox-loaded PEG-EGCG 
micelle (10kPE-1U), we observed an initial stage of rapid Dox release to reach ~ 30 % over the 
first 48 h (Figure 2-8 b). Subsequently, Dox release slowed down and no further increment was 
observed up to 120 h. The low cumulative release and gradual retardation of Dox release is in 
line with the high stability of micelles and is probably a direct result of the strong binding 
between Dox and EGCG within the micelle core. This finding suggests that Dox leakage from 
PEG-EGCG micelles in the blood stream could be minimized. 
Figure 2-8. In vitro release profile of Dox from PEG-EGCG micelles. (a) PEG-EGCG (Mw 5,000) micelles of 




2.3.6. Cytotoxicity of Dox-loaded PEG-EGCG micelles against HAK-1B cells in vitro 
Upon reaching the tumor site, it is imperative the Dox-loaded PEG-EGCG micelles could 
exert toxicity against cancer cells. Hence the cytotoxicity of Dox-loaded PEG-EGCG micelles 
was evaluated against C-26 colon carcinoma and HAK-1B liver carcinoma cells in vitro. Free 
Dox was used as comparison. The results in Figure 2-9 a clearly illustrates that the viability of C-
26 cells decreased as a function of increasing Dox equivalent concentrations of Dox-loaded 
PEG-EGCG (Mw 5,000) micelles. We also found that increasing PEG-EGCG to Dox feed 
weight ratio of micelles led to an increase in cytotoxicity (5kPE-2 > 5kPE-1 > 5kPE-0.5 > 5kPE-
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0.25). In comparison, free Dox displayed much higher cell-killing efficacy than all the micelle 
compositions. The concentrated Dox-loaded PEG-EGCG micelle - 10kPE-1U also demonstrated 
concentration dependent toxicity against HAK-1B cells (Figure 2-9 b). Although its toxicity was 
much lower than free Dox, the micelle (10kPE-1U) showed a significant enhancement in toxicity 
over time; from an IC50 of ~ 2 µg/ml at 48 h to ~ 0.25 µg/ml at 72 h. This extended toxicity 
towards HAK-1B cells could be attributed to the gradual release of Dox encapsulated in the 
micelles.  
To assess the cellular uptake and distribution, confocal microscopy was used to compare 
the intracellular trafficking of free Dox and 10kPE-1U in HAK-1B cells. The representative 
images are presented in Figure 2-10. Strong Dox fluorescence was observed in cell nuclei after 4 
h of cell incubation with free Dox. Longer incubation period of 24 h led to more intense Dox 
fluorescence in the nuclei. In contrast, we detected weak Dox fluorescence in 10kPE-1U treated 
cells at 4 h and majority of Dox fluorescence was observed in the cytoplasm rather than the cell 
nuclei. When cells were incubated with 10kPE-1U for 24 h, Dox fluorescence in cytoplasm was 
increased significantly and some nuclear localization of Dox was observed. The rate of Dox 
accumulation in cells was observed to be much faster for free Dox as compared to Dox-loaded 
micelle probably because free Dox could enter the cell rapidly by passive diffusion while 
micelles were reported to gain access through the slower endocytosis pathway [28, 39]. While it 
is possible that the slower uptake may also be ascribed to the delayed release of Dox from the 
micelles, the difference in distribution pattern of Dox intracellularly suggests otherwise. Unlike 
the intense nuclear localization visible with free Dox treatment, strong fluorescence was located 
mainly in the cytoplasm (possibly within the endosomal or lysosomal compartments) of cells 
treated with micelles. This indicates that intact Dox-loaded micelles, rather than the released free 
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Dox, were internalized. It is expected that free Dox was then slowly released from the micelles 
after cellular uptake via endocytosis. This is supported by our previous finding of enhancement 
in micelle cytotoxicity over time. 
Figure 2-9. In vitro cytotoxicity of Dox-loaded PEG-EGCG micelles and free Dox on (a) C-26 murine colon 
cancer cells after incubation for 48 h and (b) HAK-1B human liver carcinoma cells after incubation for 48 h 
and 72 h respectively (n = 5). 
 
 
Figure 2-10. Confocal microscopy images of HAK-1B cells incubated with free Dox for (a) 4 h and (c) 24 h; 
and with Dox-loaded PEG-EGCG micelles for (b) 4 h and (d) 24 h. For each panel, left image shows the cells 
with Dox fluorescence, and the right image shows the overlay of Dox fluorescence with nuclear staining by 




2.3.7. Antitumor efficacy of Dox-loaded PEG-EGCG micelles in vivo 
2.3.7.1. Antitumor efficacy on C-26 tumor model  
The antitumor efficacy of micelles was evaluated firstly on the C-26 murine colon 
carcinoma model, with free Dox as control. The formulations were injected intravenously 3 
times on days 0, 4 and 7 in nude mice bearing C-26 tumors. A survey of the literature showed 
that 10 mg/kg was the maximum dosage for free Dox in C-26 in vivo tumor study as toxicity was 
significant above this dose [40, 41]. Hence we included 10 mg/kg free Dox for comparison. We 
observed that free Dox at 10 mg/kg demonstrated significant tumor regression compared to PBS 
group (Figure 2-11 a). In contrast, all the Dox-loaded PEG-EGCG micelles did not show 
significant tumor growth inhibition at 10 mg/kg Dox equivalent concentration compared to PBS 
control. We also failed to observe any tumor growth inhibition at an even higher micelle dosage 
of 20 mg/kg. The tumor regression of free Dox treatment was accompanied by severe toxicity. 
Mice treated with free Dox experienced a steady decline in body weight that led to their toxic 
death in 10 days. On the other hand, the Dox-loaded PEG-EGCG micelles did not show any 
adverse effects on body weights of mice even at 20 mg/kg (Figure 2-11 b). These results suggest 
that Dox-loaded PEG-EGCG micelles were less toxic than free Dox against both tumor and other 
healthy organs. The lack of antitumor efficacy prompted us to escalate micelle dosages even 
further to 30 mg/kg and 40 mg/kg. The micelle treatments at these higher dosages were well-
tolerated in mice with little effect on body weight but still no tumor growth inhibition effect was 
observed (Figure 2-11 c, d). It is worth mentioning that the mice had to be euthanized at a 
relatively early stage (10 days) into the study because of rapid tumor proliferation, leading to 
excessive tumor burden. It is possible that the high stability and slow drug release property of the 
micelles may have resulted in delayed antitumor effect, leading to lack of therapeutic efficacy in 
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this period of observation. Meanwhile, we also prepared Dox-loaded PEG-EGCG micelles with 
PEG-EGCG of other molecular weights beside 5,000 (5kPE), including 10,000 (10kPE), 20,000 
(20kPE) and 30,000 (30kPE) using the exact same method as the 5kPE micelles. PEG has been 
widely used as a hydrophilic surface coating for nanoparticle drug carriers to evade body’s 
immune cells and increase circulation time [42]. As such, many studies have reported that PEG 
molecular weight may have an influence on many important parameters such as stability, 
biodistribution, pharmacokinetics of nanoparticles [36, 43, 44]. Thus we evaluated the effect of 
PEG molecular weight on antitumor efficacy of these micelles in vivo using the C-26 tumor 
model. We observed that the Dox-loaded PEG-EGCG (Mw 10,000) micelles, in particular 
10kPE-1, showed the most promise in suppressing tumor proliferation (Figure 2-11 e). 
Moreover, all the micelle treatments did not have an adverse effect on body weights of mice 
(Figure 2-11 f). Therefore, we chose the PEG-EGCG (Mw 10,000) micelle 10kPE-1 for further 





Figure 2-11. Effect of increasing dosage of Dox-loaded PEG-EGCG (Mw 5,000) micelles on (a, c) tumor 
growth and (b, d) body weight of mice bearing C-26 subcutaneous tumors (n = 5). Free Dox 10 mg/kg was 
used as comparison. Effect of PEG-EGCG molecular weight on (e) tumor volume and (f) body weight of C-26 
tumor-bearing mice treated with Dox-loaded PEG-EGCG micelles using a fixed dosage of 7.5 mg/kg (n = 3). 




2.3.7.2. Antitumor efficacy on HAK-1B tumor model  
To address the limitation of the previous in vivo tumor model, we performed a new set of 
in vivo experiments using another tumor model - HAK-1B. HAK-1B human liver carcinoma 
cells were selected instead of C-26 murine colon carcinoma cells for some reasons. First, the 
HAK-1B cancer cell line is derived from human patient [45], thus making it more clinically 
relevant than the C-26 colon carcinoma, which originates from mouse. Second, HAK-1B tumor 
was reported to develop at slower rate than C-26 tumor [46]. Previously, we noted that rapid 
growing C-26 tumor did not respond well to PEG-EGCG micelle treatment. As the micelles had 
high stability and released Dox slowly over a sustained period, we hypothesize that the 
therapeutic effect of micelle may be prolonged and more apparent on slow-growing tumors such 
as HAK-1B. Third, slow tumor growth also mirrors the clinical situation. In such cases, more 
organized and less permeable vasculatures are given time to develop, making the tumors difficult 
to treat using conventional nanocarriers via EPR targeting [47, 48]. Henceforth, the antitumor 
efficacy of the optimized Dox-loaded PEG-EGCG (Mw 10,000) micelles (10kPE-1U) was 
evaluated using HAK-1B tumor model. 
Apart from 10kPE-1U, two other Dox formulations – stand-alone Dox and DOXIL were 
also used for comparison in the in vivo study. DOXIL, which is one of the most successful drug 
carriers to date, is a PEGylated liposomal formulation of Dox clinically approved for the 
treatment of Karposi’s sarcoma and epithelial ovarian cancer [7]. From the C-26 in vivo study 
(Figure 2-11), we observed that dosage of 10 mg/kg free Dox was effective in retarding tumor 
growth but also lethal in mice while dosages of up to 40 mg/kg of Dox-loaded PEG-EGCG 
micelles were non-toxic overall. This suggests that Dox-loaded PEG-EGCG micelles probably 
have a much higher effective dose. In order to establish a fair comparison of Dox-loaded PEG-
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EGCG micelles with the other Dox formulations, the therapeutic efficacy should be evaluated at 
their respective effective doses. A search on DOXIL revealed that its maximum tolerated dose is 
similar to free Dox [49].Therefore we set the maximum dosage of both free Dox and DOXIL at 
10 mg/kg and chose 3 dosages below that – 1, 2 and 5 mg/kg to approximate the effective dose. 
In contrast, since Dox-loaded PEG-EGCG micelles were projected to have a much higher 
effective dose, we tested 2 markedly higher dosages - 25 mg/kg and 50 mg/kg. All three 
formulations were administered via tail vein injections on days 0, 4 and 7 into BALB/c nude 
mice bearing subcutaneous HAK-1B tumors. Figure 2-10 illustrates the results of the tumor 
growth inhibition study. As expected, we observed greater tumor growth inhibition effect for free 
Dox as the dosage was raised (Figure 2-12 a). However, the mice also suffered from greater 
toxicity as reflected by the decrease in mean body weight (Figure 2-12 b). Dosage of 10 mg/kg 
resulted in severe toxicity as evident from the dramatic decline in body weights leading to 
eventual deaths of animals. Similar results on tumor volume (Figure 2-12 c) and body weight 
(Figure 2-12 d) were obtained for DOXIL treatment group. In addition, at 5 mg/kg for both free 
Dox and DOXIL, no significant tumor suppression compared to PBS group was observed (p > 
0.05). We observed that increasing the dosage of 10kPE-1U also enhanced tumor growth 
inhibition (Figure 2-12 e). In contrast to the toxicity profile of free Dox and DOXIL, at 
noticeably higher dosages of 25 and 50 mg/kg, micelle treatment induced little toxicity in mice, 
based on the small variation in mean body weight (Figure 2-12 f). The attenuation in systemic 
toxicity could be a direct result of the high stability and little Dox leakage of PEG-EGCG 
micelles during circulation, contributing to reduced unspecific distribution of Dox to non-target 
sites. More importantly, we noted that 10kPE-1U at 50 mg/kg dosage demonstrated significant 
tumor growth inhibition compared to PBS group (p < 0.05), possibly due to passive targeting of 
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micellar nanoparticles by EPR effect. It is worth to highlight that 10kPE-1U demonstrated 
superior anticancer efficacy than the optimal dosages of both clinically used Dox formulations in 
this experiment setting. This could probably be attributed to the higher dosage of micelles 
administered, contributing to increased Dox tumor localization compared to free Dox and 
DOXIL. Overall as a result of enhanced stability and reduced toxicity, Dox-loaded PEG-EGCG 





Figure 2-12. In vivo antitumor efficacy of various Dox formulations in the HAK-1B tumor-bearing mouse 
model. Three i.v. injections of various Dox equivalent doses of free Dox, DOXIL and Dox-loaded PEG-EGCG 
micelle were administered on the days indicated by arrows. Effect of free Dox 1 – 10 mg/kg on (a) relative 
tumor size and (b) body weight; Effect of DOXIL 1 – 10 mg/kg on (c) relative tumor size and (d) body weight; 
Effect of 10kPE-1U 25 mg/kg and 50 mg/kg on (e) relative tumor size and (f) body weight (n = 8 - 10). Data is 





Dox-encapsulated PEG-EGCG micelles were formed by the self-assembly of PEG-
EGCG conjugates and Dox in aqueous solution, triggered by the interactions between EGCG 
moieties and Dox molecules. As a result of strong interactions between Dox and EGCG, these 
Dox-loaded PEG-EGCG micelles were observed to have a remarkably high drug loading content 
of up to 86 %, high stability and slow release rate. As a result of high stability and minimal drug 
leakage in circulation, Dox-loaded PEG-EGCG micelle demonstrated reduced toxicity in vivo 
and a much elevated maximum tolerated dose free compared to two clinically relevant Dox 
formulations - Dox and DOXIL. Most notably, Dox-loaded PEG-EGCG micelle at 50 mg/kg 
achieved more significant tumor growth inhibition effect against HAK-1B subcutaneous tumors 
compared to optimal dosages of both Dox and DOXIL. Taken together, this work demonstrated 
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Chapter 3: Targeted intracellular protein 
delivery based on hyaluronic acid-green tea 




Despite recent progress in protein carrier design, the delivery of functional proteins 
intracellularly still remains a challenge. In order to deliver proteins into the cytosol, several 
obstacles have to be overcome, including penetration of the cell membrane, resistance to 
degradation by lysosomal enzymes as well as release from the endosomal compartments [1]. 
More recently, intracellular delivery of cytotoxic proteins has generated potential interest for 
cancer therapy. More specifically, delivery of cytotoxic protein cargoes such as RNase A and 
caspase-3 have been explored for this purpose [2-4]. However, there remains a considerable gap 
between cancer cells recognition and cargo delivery. To this end, a liposomal nanocarrier with 
anisamide decorated surface has been designed to deliver cytochrome C (Cyt C) intracellularly to 
target lung tumors [5]. 
Among all the polymeric nanocarrier formulations, nanogels have received increasing 
interest as efficient carriers for various proteins. Their advantages include reversible binding to 
proteins without the need for chemical modification, protection from degradation by proteases, 
controllable release profile and high stability [6]. For instance, Akiyoshi et al. developed self-
assembling cholesterol-grafted pullulan (CHP)-based nanogels to successfully encapsulate, 
stabilize and deliver interleukin-12 (IL-12) in vivo [7]. Ethylenediamine group functionalized 
pullulan nanogels have also achieved delivery of bovine serum albumin (BSA) and β-
galactosidase into Hela cells [8]. Additionally, Park et al. have shown that heparin-pluronic 
nanogels could be used for the intracellular delivery of RNase A [4]; and paclitaxel and DNase  
simultaneously [9] to achieve significant anticancer effects.  
In particular, hyaluronic acid (HA) is often chosen as a component of the nanogel 
formulations because of its ability to target HA receptor - CD44, overexpressed in many cancer 
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cells including cancer stem cells [10, 11]. Lee et al. synthesized HA/siRNA nanogels to 
selectively target CD44 overexpressing HCT-116 colon cancer cells in vitro [12], while Wei et al.  
developed cholesterol modified HA nanogels to physically encapsulate and deliver small 
molecule drugs etoposide and salinomycin to kill cancer stem cells [11]. Thus, it is predicted that 
the incorporation of HA would not only enable targeted delivery of payload into cancer cells.  
Here, we introduce the design of a novel polymeric carrier comprising HA-EGCG 
conjugate for the targeted intracellular delivery of proteins into cancer cells. The HA backbone 
affords the active targeting motif for CD44 that is overexpressed in many types of cancer cell. 
On the other hand, EGCG, the main component of green tea catechins, is well known for its anti-
oxidative and anti-carcinogenic properties [13, 14]. Since EGCG has an ability to bind protein 
[15, 16], we expect that the conjugation of EGCG to the HA backbone allows for the 
complexation of the HA-EGCG carrier with the protein of interest.  
The protein we chose is Granzyme B (GzmB). It is a serine protease secreted by the 
cytotoxic T-cells and natural killer cells in response to foreign cells invasion. When it is present 
in the cell cytosol, it initiates a caspase activation cascade, leading to apoptosis. The entry of 
GzmB into target cells is normally mediated by a membrane destabilizing protein – perforin [17]. 
Some studies also found that even though GzmB could be internalized by cells, it is unable to 
cause apoptosis unless perforin is added simultaneously [18, 19]. Our objective is to make use of 
HA-EGCG conjugate to chaperon GzmB into cytosol of cancer cells. To this end, we prepared 
nanogel complexes comprising HA-EGCG, GzmB and linear polyethyleneimine (PEI). Physical 
interactions between HA-EGCG and GzmB and PEI provide the driving force for self-assembly 
(Figure 3-1 a). HA-EGCG coating on nanogel surface allows for the targeted delivery of nanogel 
complexes into cancer cells via CD44-mediated endocytosis. PEI is used to facilitate the release 
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of GzmB in the cytosol. The presence of multiple cationic amine groups on PEI is widely known 
to have high buffering capacity in the acidic environment of the endosomal compartments of 
cells [20], which subsequently results in the endosome disruption. Finally, GzmB would be 
released into cytoplasm to achieve cancer cell apoptosis (Figure 3-1 b).  
 
 
Figure 3-1. (a) Formation of self-assembled nanogel complexes comprising HA-EGCG, PEI and GzmB; (b) 
CD44-mediated uptake of nanogel and the facilitation of GzmB release by PEI from endosome, which 
triggers apoptosis in cancer cells. 
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3.2. Materials and Methods  
3.2.1. Materials 
Hyaluronic acid (HA, 90 KDa) was kindly donated by JNC Corporation (Tokyo, Japan). Fmoc-
Ala-aldehyde was purchased from Bachem (Switzerland). EGCG (TEAVIGO) was purchased 
from DMS Nutritional Products Ltd (Switzerland). Tetrahydrofuran (THF), methanesulfonic acid 
(MSA), N-hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC⋅HCl), dimethylformamide (DMF), triethylamine (TEA), lysozyme from 
chicken egg white, lysozyme substrate Micrococcus lysodeikticus, mouse Granzyme B (GzmB) 
and chloroquine diphosphate were all purchased from Sigma-Aldrich. Exgen 500 transfection 
reagent (Linear PEI 22 kDa) was obtained from Fermentas INC. AlamarBlue® was purchased 
from Invitrogen. CD44 antibody (156-3C11) was purchased from Novus Biologicals. 
BioPORTER® was acquired from Gelantis. Phosphate buffer saline (PBS, 150 mM, pH 7.3) was 
supplied by the media preparation facility in Biopolis, Singapore. 
3.2.2. Synthesis of HA-EGCG conjugates 
HA-EGCG conjugates were synthesized in a 3-step process. The first step was 
synthesizing Fmoc-Ala-bridged EGCG dimer, which was synthesized in a similar fashion to a 
protocol developed in our laboratory [21] with minor modifications (Scheme 3-1). EGCG (15.5 g, 
33.8 mmol) was dissolved in 50 ml of anhydrous THF by stirring at room temperature. Then, 
Fmoc-Ala-aldehyde (1 g, 3.4 mmol) was added, followed by 162 µl of MSA. The mixture was 
incubated at room temperature for 24 h. Next day, the product was precipitated out by adding 
450 ml of H2O to the mixture while stirring vigorously. The precipitate was collected by 
centrifugation at 10000 rpm for 5 min. The product was re-dissolved in 10 ml of THF and then 
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precipitated again with 100 ml of H2O. The precipitation cycle was repeated till all monomeric 
EGCG was removed from the product as determined by LC/MS (Acquity UPLC equipped with 
SQD single quadrupole detector (Waters, Milford, MA). Gradient elution was done using 
Acquity UPLC BEH C18 Column (1.7 µm, 2.1 x 100 mm) starting from water:acetonitrile (95:5, 
v/v) to (20:80 v/v) in 8 min at a flow rate of 0.5 ml/min). After that, the product was dried 
overnight under vacuum at room temperature. Yield: (3.3 g, 82 %).  
 
Scheme 3-1. Synthesis of Fmoc-Ala-bridged EGCG dimer. 
The second step consisted of the deprotection of Fmoc-Ala-bridged EGCG dimer. It was 
performed with 50 % TEA in DMF (Scheme 3-2). Fmoc-Ala-bridged EGCG dimer (3.3 g, 2.76 
mmol) was first dissolved in 12.4 ml of DMF. Then, 12.4 ml of TEA was added dropwise into 
the mixture while stirring vigorously. The mixture was incubated for 8 h to ensure complete de-
protection. After which the mixture was centrifuged and the clear supernatant collected. One 
hundred and fifty ml of dichloromethane was added to the supernatant, and the resultant 
precipitate was collected by filtration. The product was washed twice with 30 ml of 
dichloromethane and then dried overnight under vacuum at room temperature. Yield: (3.2 g, 




Scheme 3-2. Deprotection of Fmoc-Ala-bridged EGCG dimer. 
The final step involved conjugating the Ala-bridged EGCG dimer onto HA, by a 
conventional carbodiimide reaction (Scheme 3-3). HA (700 mg, 1.83 mmol) was dissolved in 60 
ml of MilliQ water by stirring. The carboxylic acid of HA was activated by adding NHS (420 mg, 
3.66 mmol) and EDC⋅HCl (700 mg, 3.66 mmol). The pH of the mixture was maintained at 4.7 
for 5 h. Next, Ala-bridged EGCG dimer (1.8 g, 1.83 mmol) dissolved in 20 ml of DMF:HCl 
mixture (19:1) was added dropwise to the mixture and the pH was adjusted to 4.7. To prevent the 
oxidation of EGCG, oxygen was removed from the mixture by three cycles of degassing 
(vacuum/sonication) and refilling with N2. The mixture was incubated overnight at room 
temperature. The purification of HA-EGCG conjugates was done by precipitation according to 
previously established protocol [22]. Briefly, the pH of the mixture was lowered to 3, and then 
368 ml of MilliQ water and 49 ml of 5 M NaCl were added. Then, the HA-EGCG conjugate was 
precipitated by addition of 912 ml of EtOH. The precipitate was collected by centrifugation. The 
precipitation cycle was repeated twice (2nd cycle: MilliQ water (795 ml), 5 M NaCl (88 ml) and 
EtOH (1.8 L); 3rd cycle: MilliQ water (1.6 L), 5 M NaCl (176 ml) and EtOH (3.65 L)) to remove 
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unconjugated Ala-bridged EGCG dimer. Finally, the HA-EGCG conjugate was dissolved in 450 
ml of MilliQ water and dialyzed against MilliQ water using a dialysis membrane (Mw cut-off: 
3500 Da) at pH 3.5 overnight under N2 atm. The product was freeze-dried. Yield: 320 mg. To 
determine the degree of substitution (number of Ala-EGCG dimers conjugated for every 100 
disaccharide units), the conjugates were dissolved at 0.1 mg/ml in water and UV-Vis spectrum 
was recorded with a Hitachi U-2810 spectrometer (Figure 3-2). The amount of EGCG contained 
in the conjugate was determined by comparing the absorbance at 274 nm with a set of EGCG 
standards. The degree of substitution was found to be 2.3.  
Scheme 3-3. Synthesis of HA-EGCG conjugate. 
  
Figure 3-2. UV-VIS spectrum of HA-EGCG and HA in water. The concentrations of both HA-EGCG and HA 
were 100 µg/ml. 





Stock solutions of HA-EGCG, HA, linear PEI and lysozyme were prepared in MilliQ 
water. One hundred µl of PEI (100 µg/ml) was added to 100 µl of lysozyme (200 µg/ml) at room 
temperature. After 5 min, 200 µl of HA-EGCG (1 mg/ml) and 600 µl of MilliQ water were 
added to the mixture. HA was also utilized as a comparison. The mixture solution was then 
incubated for 1 h at room temperature to form nanogel complexes before the measurement of 
dynamic light scattering (ZetaPALS, Brookhaven Instrument Corp., Holtsville, NY, USA). The 
measurements were done in quintuplicates. For the measurement of zeta potential (Zetasizer, 
Malvern Instrument Ltd., Worchestershire, UK), 100 µl of PEI (10 µg/ml) was added to 100 µl 
of lysozyme (20 µg/ml) at room temperature. After 5 min, HA-EGCG of different concentrations 
and MilliQ water were added to the mixture. The total volume of the final mixture was 1 ml. 
Measurements were performed in triplicates after 1 h incubation at room temperature. All data 
are expressed as the mean ± standard deviation. 
3.2.4. Binding studies by fluorescence measurement  
Quenching of intrinsic lysozyme fluorescence was used to monitor the binding 
interactions between HA-EGCG and lysozyme. Stock solutions of HA-EGCG, HA or EGCG at 1 
mg/ml were prepared in MilliQ water. These solutions were diluted to various concentrations 
using PBS and mixed with lysozyme fixed at a concentration of 100 μg/ml. After incubation at 
room temperature for 1 h, fluorometric measurements were performed using a Hitachi 
spectrofluorometer model F-2500 using an excitation wavelength of 295 nm. Emission spectra 
were recorded from 305 to 400 nm. The emission intensities at 339 nm, which were found to be 
the emission peaks, were compared among the different samples. All measurements were done in 
triplicates. For EGCG and HA-EGCG, the fluorescence intensity was corrected using a known 
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formula [23] since the emission peak of lysozyme at 339 nm overlapped with EGCG absorption. 
The equation to obtain the actual fluorescence intensity F is given below: F = Fu × 10Q (S𝜆𝑒𝑥+S𝜆𝑒𝑚 ) 
where Fu  is the measured, uncorrected emission intensity.  S𝜆𝑒𝑥  and S𝜆𝑒𝑚  are slopes of 
absorbance versus concentration linear plots of EGCG and HA-EGCG standards at the excitation 
(295 nm) and emission wavelengths (339 nm) respectively. Q refers to the concentration of 
EGCG or HA-EGCG. Subsequently the fluorescence intensity ratio was calculated using the 
following equation: 
alone lyosozyme ofintensity  ceFluorescen
sample ofintensity  ceFluorescen)(F/F RatioIntensity  ceFluorescen 0 =
 
where F is the corrected fluorescence intensity and 0F is the intrinsic fluorescence intensity of 
lysozyme alone. 
3.2.5. Lysozyme activity assay 
Nanogel complexes comprising HA-EGCG, lysozyme and PEI were prepared in the 
eppendolf tubes in a similar manner as described above. Lysozyme and PEI concentrations were 
fixed at 20 and 2 μg/ml respectively but HA-EGCG of different concentrations was used. All the 
samples were then incubated for 30 min for complexation to occur. To determine the activities of 
lysozyme, they were transferred to the wells of a 96-well UV microplate followed by 100 μl of 
Micrococcus lysodeikticus (0.15 w/v % in PBS). The plate was then shaken for 15 s orbitally 
before absorbance at 450 nm was measured using the microplate reader. The absorbance decay 
plot was fitted to a linear equation, and the slopes were used to determine lysozyme activities of 
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the samples. The lysozyme activities were calculated as a percentage of the activity of lyoszyme 
alone using the following equation:  
100
sampleut plot withodecay  absorbance of Slope
sampleplot with decay  absorbance of Slope(%)Activity  Lysozyme ×=  
To determine the restoration of lysozyme activity, Triton-x 100 solutions of different 
concentrations were prepared in PBS and were added to the nanogel complexes and incubated 
for 5 min. Then the mixtures were added to the wells of the 96-well plate and activities of 
lysozyme were determined by the aforementioned method.  
3.2.6. Cell viability assay  
HCT-116 human colorectal carcinoma cells were seeded at 20,000 cells per well in BD 
Falcon 96-well microplates with complete growth medium (McCoy’s 5A, 10 % (v/v) FBS, 1 % 
(v/v) penicillin/streptomycin) and left to attach for 48 h. Nanogel complexes comprising HA-
EGCG, GzmB and PEI were prepared by firstly adding PEI to GzmB and letting the mixture sit 
for 20 min at room temperature. Following that, HA-EGCG was added and the resultant 
complexes were incubated for another 30 min. The concentrations of HA-EGCG were varied but 
GzmB and PEI concentrations were kept at 2 and 1 μg/ml respectively. The mixture solution of 
GzmB and chloroquine (CQ) (100 µM) was also prepared as a positive control. In addition, 
complexes of GzmB (2 μg/ml) with Bioporter® were also prepared according to the protocol 
provided by Genlantis, USA. In a separate experiment, another set of nanogel complexes was 
prepared in a similar manner as described above, using various combinations of PEI, GzmB and 
HA or HA-EGCG. The final concentrations of PEI, GzmB and HA/HA-EGCG were fixed at 1, 2 
and 10 µg/ml respectively. In all the experiments, cell viability was analyzed using AlamarBlue® 
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after 48 h treatment. Briefly, the culture medium was aspirated and the cells were gently washed 
with PBS once before fresh medium with AlamarBlue® 10 % (v/v) was added to each well. The 
cells were incubated for 2 h and the fluorescence measurement was performed using a Tecan 
Infinite Microplate Reader. Excitation and emission wavelengths were set at 545 and 590 nm, 
respectively. The results were expressed as percentage of viability compared with untreated cells. 
All results are expressed as the mean ± standard deviation of quadruplicates. The same procedure 
was repeated for HepG2 human liver carcinoma cells cultured with Dulbecco’s modified Eagle’s 
medium (DMEM). 
3.2.7. Conjugation of FITC to lysozyme 
Briefly, 2 mg of Fluorescein-5-isothiocyanate, (FITC) (Invitrogen) and 200 mg of 
lysozyme were dissolved in 0.1 M borate buffer (pH 9.0). After incubation for 60 min at room 
temperature, pH was adjusted to 7.5 with 0.1 M boric acid. The solution was dialyzed for 72 h at 
4 oC while refreshing distilled water twice daily. Subsequently, the final product was obtained by 
lyophilization. The isolated FITC-lysozyme was then characterized by UV-VIS absorption 
spectroscopy, and the labeling efficiency was found to be 3.5 moles FITC per mole of protein.  
3.2.8. Flow cytometry studies 
The cells (HCT-116 or HepG2) were first harvested from culture flasks by trypsin 
treatment. The cells were then incubated with primary CD44 antibody for 30 min. In addition, 
the cells were also treated with PBS and isotype control in parallel to confirm that the signal was 
a result of the CD44 antibody binding only. After that, the samples were centrifuged and washed 
with PBS three times to remove the background fluorescence. Following that, FITC-labeled 
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secondary antibody was added and left to attach for 30 min. After another three cycles of 
washing and centrifugation, cells were resuspended with 200 μL of PBS. The extent of cells 
which was stained positive for CD44 was evaluated by FACSCalibur flow cytometer (BD 
Biosciences, USA). 
3.2.9. Intracellular caspase imaging 
Fluorescence imaging of caspases was performed with the Image-iT ™ LIVE Red 
Caspase-3 and -7 Detection Kit (Invitrogen). HCT-116 cells were seeded in 8-well chamber 
slides at density of 20,000 cells/well with complete growth medium (McCoy’s 5A with 10 % 
FBS) and allowed to attach for 48 h. After that, they were treated with nanogel complexes with 
and without PEI and incubated for 5 h. The staining procedure was then performed in accordance 
with the staining protocol provided by Invitrogen. The cells were then viewed immediately under 
a confocal laser scanning microscope (Zeiss LSM 510 META). 
3.2.10. Intracellular trafficking studies 
HCT-116 cells were seeded in 8-well chamber slides (Lab-Tek®) at density of 20,000 
cells/well with complete growth medium (McCoy’s 5A with 10 % FBS) and left to attach for 24 
h. Nanogels were similarly prepared as the cell viability study, but FITC-labeled lysozyme was 
used instead of GzmB. The FITC-lysozyme concentration was fixed at 20 µg/ml. The cells were 
then incubated with the nanogel complexes for 16 h in the dark. Subsequently, the cells were 
washed twice with ice-cold PBS and fixed with fresh 4 % paraformaldehyde for 15 min at room 
temperature. The cell nuclei were then stained with 4, 6-diamidino-2-phenylindole (DAPI) and 
visualized using confocal microscopy. 
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3.3. Results and Discussion 
3.3.1. Synthesis and characterization of HA-EGCG conjugate 
In this study, HA-EGCG was synthesized by a condensation reaction between Ala-
bridged EGCG dimer and carboxyl group of HA. Fmoc-Ala-bridged EGCG dimer was 
synthesized by the aldehyde-mediated reaction between Fmoc-Ala-aldehyde and A-ring of 
EGCG. Subsequently, the Fmoc group was deprotected. In the final step, Ala-bridged EGCG 
dimer was conjugated to HA by conventional carbodiimide reaction.  
The Fmoc-Ala-bridged EGCG dimer intermediate was characterized by various Mass 
Spectroscopy techniques. It was firstly characterized by Liquid Chromatography Mass 
Spectroscopy (LCMS) (Figure 3-3 a). The UV-absorbance peaks indicated the presence of 
EGCG containing products and the four peaks that were observed could possibly be attributed to 
the isomers of Fmoc-Ala-bridged EGCG dimer. This is because the conjugation site between the 
EGCG and Fmoc-Ala-aldehyde could be at either the 6’ or 8’ position of A-ring of EGCG, 
giving rise to four isomeric configurations - 6-6, 6-8, 8-6 and 8-8. We presumed that the peak at 
m/z 1194.50 observed in the representative mass spectrum corresponded to the product Fmoc-
Ala-bridged EGCG dimer (Mw 1193 Da). To confirm the identity of the signal, mass analysis 
was performed using two more methods – Fast-Atom Bombardment Mass Spectroscopy 
(FABMS) (Figure 3-3 b) and high resolution Electron Spray Ionization-Mass Spectroscopy (ESI-
MS negative ionization) (Figure 3-3 c). Both the FABMS and high resolution ESI-MS yielded a 
prominent peak at m/z ratio 1192, which was consistent with the mass of the Fmoc-Ala-bridged 
EGCG dimer intermediate. Taken together, the characterizations indicated that the synthesis of 
Fmoc-Ala-bridged EGCG dimer was successful. Subsequently, we continued with the following 
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steps of HA-EGCG synthesis. The EGCG content in the final product HA-EGCG was measured 
by comparing the UV absorbance of HA-EGCG against a standard curve for EGCG with 






Figure 3-3. Characterizations of Fmoc-Ala-bridged EGCG dimer (a) Liquid Chromatography Mass 
Spectroscopy (LCMS), (b) Fast-Atom Bombardment Mass Spectroscopy (FABMS) and (c) Electron Spray 
Ionization-Mass Spectroscopy (ESI-MS negative ionization) at high resolution. 
 
3.3.2. Characterizations of HA-EGCG nanogel  
3.3.2.1. Size and zeta potential of HA-EGCG nanogels 
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We used a model protein, lysozyme, to study the complexation behavior between HA-
EGCG and GzmB. Lysozyme (Mw 14.3 kDa, pI 9.20) was chosen because it has relatively 
similar molecular weight and isoelectric point as GzmB (Mw 30 kDa, pI ~10). First we studied 
the particle size of the nanogel by dynamic light scattering. The ternary nanogel complex 
comprising of HA-EGCG/lysozyme/PEI was found to have a size of around 160 nm (Figure 3-4 
a). In contrast, the HA/lysozyme/PEI complex control had a size of 222 nm (Figure 3-4 b). 
Furthermore, the HA-EGCG nanogel was observed to have much lower polydispersity with a 
single size distribution whereas HA nanogel had two disparate distributions. The hydrophobic 
and π-π stacking interactions between EGCG moiety and amino acid residues in lysozyme 
possibly led to stronger binding, resulting in smaller nanogel particulates. In contrast, 
HA/lysozyme/PEI particles was probably held together weakly by ionic interactions between the 
carboxylate anion of HA chain and positively charged amino acid residues lysozyme.  
Figure 3-4. (a) Dynamic light scattering data of HA-EGCG/Lysozyme/PEI nanogel complex and (b) 
HA/Lysozyme/PEI complex, at concentrations of 200 µg/ml, 20 µg/ml and 10 µg/ml respectively; (c) Zeta 
potential measurements of nanogel complexes with increasing HA-EGCG concentration. 
 
The baseline index of HA-EGCG/lysozyme/PEI nanogel complexes was also consistently 
higher than that of HA/lysozyme/PEI complexes (Table 3-1). Baseline index is an indication of 
sample quality, which refers to the difference between the measured baseline and calculated 
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baseline of the autocorrelation function. In practical terms, a low sample quality signaled the 
presence of large particles or aggregates. All in all, these results indicated that HA-
EGCG/lysozyme/PEI nanogel complexes were more stable and homogeneous than 
HA/lysozyme/PEI mixture.  
Table 3-1. Dynamic light scattering results of HA-EGCG nanogels and HA control. 
Samples Size (nm) Polydipersity Baseline Index 
HA/lysozyme/PEI 222.8 ± 4.9 0.155 ± 0.017 7.0 ± 1.7 
HA-EGCG/lysozyme/PEI 159.8 ± 3.2 0.101 ± 0.019 9.1 ± 0.8 
 
Next we examined the effect of HA-EGCG concentration on the surface charge of the 
nanogel complexes with fixed concentrations of lysozyme (2 µg/ml) and PEI (1 µg/ml). As 
shown in Figure 3-4 c, the zeta potential of the HA-EGCG nanogel complexes decreased with 
increasing HA-EGCG concentrations due to the negatively charged carboxylate anions on HA. 
In particular, zeta potential became negative when HA-EGCG concentrations exceeded 5 µg/ml. 
Since zeta potential is an indication of the charge at the surface of nanoparticles, this observation 
suggested that the HA-EGCG conjugate was able to cover the surface of the nanogel complexes 
at concentrations > 5 µg/ml. 
3.3.2.2. Binding of HA-EGCG to lysozyme 
To estimate the strength of binding interactions between HA-EGCG and proteins in the 
formation of nanogel, we measured the extent of quenching of intrinsic tryptophan fluorescence 
in the proteins, based on a previously reported method [24]. The ability of HA-EGCG to quench 
lysozyme fluorescence was analyzed by comparing with both HA and EGCG at equivalent 
concentrations. The fluorescence intensities of samples were then expressed as a ratio of the 
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intrinsic fluorescence of lysozyme alone. HA alone did not quench lysozyme fluorescence, 
indicating that there was no binding (Figure 3-5 a). In contrast, HA-EGCG decreased lysozyme 
fluorescence in a concentration dependent manner and interestingly to a much greater extent than 
EGCG alone (Figure 3-5 b). For instance, HA-EGCG quenched fluorescence by 78 % at EGCG 
concentrations of 25 µg/ml whereas EGCG at 30 µg/ml only managed 30 % fluorescence 
reduction. This suggested that the conjugation of EGCG to HA enhanced the binding interaction 
between EGCG moiety and lysozyme, possibly because the HA backbone increased the local 
concentration of EGCG moieties around a lysozyme molecule. 
Figure 3-5. Comparison of fluorescence quenching abilities of various samples - (a) HA and HA-EGCG and 
(b) EGCG and HA-EGCG at equivalent concentrations. 
3.3.2.3. Complexation-dissociation behavior of HA-EGCG with lysozyme 
The complexation of HA-EGCG conjugates with lysozyme was further verified by 
lysozyme activity assay using M. lysodeikticus as the lysozyme substrate [25]. Binding of 
lysozyme to HA-EGCG would hinder enzyme-substrate reaction and that would be reflected by a 
decrease in enzymatic activity level. Indeed, we found that HA-EGCG decreased lysozyme 
activity in a concentration-dependent manner, whereas HA did not (Figure 3-6 a). Since 
complexation with HA-EGCG would hinder protein activity, dissociation of the complex to 
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release the functional protein is necessary once the nanogel complex is internalized within the 
cell, so that the protein can achieve its intended function. To investigate the ability of the 
complexes to release proteins, we destabilized the pre-prepared HA/lysozyme/PEI and HA-
EGCG/lysozyme/PEI nanogel complexes (100 µg/ml) with Triton-X, which was expected to 
disrupt the hydrophobic interactions within the complex [26]. From the results on Figure 3-6 b, 
we demonstrated that addition of 0.1 w/v % of Triton-X to the HA-EGCG nanogel complexes 
led to the successful restoration of lysozyme activity from 85 % to 99 % while no effect was 
observed for the HA counterpart.  
Figure 3-6. (a) Lysozyme activities of HA/lysozyme/PEI complex and HA-EGCG/lysozyme/PEI nanogel 
complex. (b) Addition of Triton-x successfully restored the lysozyme activity in the HA-EGCG/lysozyme/PEI 
nanogel complex. 
3.3.3. Inhibition of HCT-116 cell proliferation by HA-EGCG/GzmB/PEI nanogels 
The confirmation of the complexation-dissociation behavior of HA-EGCG with 
lysozyme and PEI motivated us to investigate the potential of GzmB as the cargo for delivery. 
As mentioned above, GzmB is a cytotoxic protein that is known to initiate apoptosis 
intracellularly. By taking advantage of the HA receptor targeting, we aimed to achieve specific 
eradication of cancer cells by using HA-EGCG nanogels to deliver GzmB into cytosol of those 
cells. HCT-116 colon cancer cells overexpressing CD44 were used for the in vitro assessment. 
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First we verified that GzmB alone did not affect cell viability (Figure 3-7 a). This agreed well 
with previous studies that showed cell death mediated by GzmB could only be observed when its 
release into cytoplasm was facilitated by perforin [18, 19]. A positive control comprising 
chloroquine (CQ), a common lysosomotropic agent, was also set up. GzmB/CQ treatment was 
observed to induce > 70 % cell death. Even though CQ was successful in enabling GzmB-
mediated cell death, its usage is undesirable as it is toxic [27]. Next we investigated the optimal 
HA-EGCG/GzmB/PEI nanogel formulation for cell inhibition. When we increased HA-EGCG 
concentration of the nanogel complexes, we observed a drop in cell viability from 2 – 10 µg/ml 
where it reached a minimum of around 48 % at an optimal HA-EGCG/GzmB/PEI concentration 
ratio of 10 µg/ml /2 µg/ml /1 µg/ml respectively (Figure 3-7 a). The effect was reversed when 
HA-EGCG increased from 10 µg /ml to 20 µg/ml. The initial increase in cytotoxicity could be 
attributed to greater stability of nanogel complex as a result of stronger binding interactions 
between HA-EGCG and GzmB. However, further enhancement of HA-EGCG GzmB 
interactions probably retarded the release of GzmB from the complex thus resulting in a drop in 
GzmB-mediated toxicity. In contrast to HA-EGCG nanogel complexes, HA complexes with 
different HA concentrations had little effect on cell viability throughout. This suggested that HA-




Figure 3-7. (a) Cell viability of HCT-116 cells after treatment with HA-EGCG/GzmB/PEI nanogels complexes 
with increasing concentrations of HA and HA-EGCG, while GzmB and PEI concentrations were fixed at 2 
µg/ml and 1 µg/ml respectively (n = 4). CQ was used as positive control. GzmB alone and Bioporter/GzmB 
treatment were used as comparison. (b) Cell viability of HCT-116 cells treated with various combinations of 
optimized HA-EGCG, HA and GzmB concentrations (n = 4). 
 
It is also worth mentioning here that so far there has been no successful delivery of 
positively charged proteins such as GzmB in a targeted manner similar to what was shown here 
because most of the carriers were designed carry positive charge to exploit the electrostatic 
interactions with the negatively charged cell membrane. One of the few carriers that has been 
reported to deliver GzmB intracellularly is Bioporter® [28], a commercial liposomal carrier. Thus 
we included Bioporter® for comparison. However we observed that Bioporter®/GzmB complex 
failed to induce significant toxicity in HCT-116 cells (Figure 3-7 a). This discrepancy could 
possibly be attributed to the difference in cell line, which may influence the efficiency of 
Bioporter® facilitated GzmB delivery.  
Subsequently various combinations of HA, HA-EGCG, GzmB and PEI complexes at the 
optimized concentrations were prepared to assess their effects on cell viability (Figure 3-7 b). 
The result showed that all other treatments besides CQ/GzmB and HA-EGCG/GzmB/PEI 
nanogel complex had no effects on cell viability, indicating that the other components were not 
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responsible for cytotoxicity. We also observed no toxicity from nanogel complexes prepared 
using the model protein lysozyme. This suggests that the toxicity induced by HA-
EGCG/GzmB/PEI nanogel complexes was the result of GzmB mediated cell killing. In addition, 
the fact that HA-EGCG/GzmB complexes alone were not able to induce cytotoxicity in the cells 
confirmed the role of PEI in facilitating intracellular GzmB delivery (Figure 3-7 b). The presence 
of PEI in the complex could be critical for the dissociation and release of GzmB in the cytosol. 
3.3.4. Induction of apoptosis by HA-EGCG/GzmB/PEI nanogels  
Successful intracellular delivery of GzmB in cytosol by nanogels would result in 
apoptosis, leading to cell death. One feature of the early stages of apoptosis is the activation of 
caspase enzymes, especially caspases-3 and 7 [29]. To assess the extent of apoptosis in cells 
treated with various complexes, we proceeded to detect intracellular caspase-3 and caspase-7 by 
a fluorescently labeled substrate using confocal microscopy. HCT-116 cells treated with 
complexes formed with HA/GzmB/PEI and GzmB/PEI mixture showed little fluorescence 
throughout (Figures 3-8 a, b). In contrast, ubiquitous fluorescence was detected in cells treated 
with HA-EGCG/GzmB/PEI, suggesting that caspase level was enhanced in those cells and 
cellular toxicity was indeed due to apoptosis (Figure 3-8 c). Presence of some activated caspase 





Figure 3-8. HCT-116 cells treated with (a) GzmB/PEI, (b) HA/GzmB/PEI (c) HA-EGCG/GzmB/PEI for 4 h 
followed by staining with fluorescently labeled caspase substrates. Scale bar = 20 µm. 
 
3.3.5. Effect of HA-EGCG/GzmB/PEI nanogels on low CD44-expressing cells  
To verify the CD44 targeting capability of the HA-EGCG/GzmB/PEI nanogel 
complexes, we investigated the effect of complexes on another cell line - HepG2, a cell line that 
was reported to have low CD44 expression [30]. CD44 expression levels were evaluated by 
Fluorescence Activated Cell Sorting (FACS) (Figure 3-9) following antibody staining in both 
HCT-116 and HepG2 cells. The results confirmed that HCT-116 cells had much higher affinity 
for CD44 antibody than HepG2 cells in which 99.1 % of HCT-116 cells displayed fluorescent 
signal as compared to 0 % in HepG2. When we investigated the effects of various combinations 
of complexes at optimized concentrations on HepG2 cell viability, we found that except for the 
CQ/GzmB treatment which induced about 60 % cell death, various combinations of HA or HA-
EGCG complexes had no effect on the cell viability (Figure 3-10). The ineffectiveness of HA-
EGCG/GzmB/PEI nanogel complexes against CD44 low-expressing cell line suggested that the 




Figure 3-9. Fluorescent-activated cell sorting results of CD44 antibody binding to HCT-116 and HepG2 cells.  
 
 
Figure 3-10. Cell viability of HepG2 cells treated with various combinations of optimized HA-EGCG, HA and 
GzmB concentrations (n = 4). CQ was used as positive control.  
3.3.6. Intracellular trafficking of HA-EGCG/FITC-lysozyme/PEI nanogels  
To further understand this difference in toxicity of nanogel complexes on the two cell 
lines, cellular uptake was elucidated by intracellular trafficking of a fluorescently labeled FITC-
lysozyme. When HCT-116 cell or HepG2 cells were incubated with HA-EGCG/FITC-lysozyme 
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complexes for 16 h, we observed much more robust uptake of FITC-lysozyme in HCT-116 cells 
as compared to HepG2 cells (Figure 3-11). Higher uptake in HCT-116 was expected as a result 
of the efficient internalization of HA-EGCG nanogel complexes by abundant HA receptors on 
HCT-116 cell surface, and that is supported by the significantly greater toxicity of the HA-
EGCG/GzmB/PEI nanogel complexes toward HCT-116 cells compared to HepG2 cells. 
Moreover, inclusion of PEI in the HA-EGCG/FITC-lysozyme complexes clearly triggered the 
release of FITC-lysozyme in HCT-116 cells, resulting in the FITC-lysozyme being evenly 
distributed throughout the cell cytosol. This agreed well with the previous observation that PEI 
played an important role in facilitating the escape of FITC-lysozyme from endosomal 
compartments within the cells.   
 
Figure 3-11. (a) Intracellular uptake of HA-EGCG/FITC-lysozyme nanogel complexes into HCT-116 cells 
without PEI; and (b) release of FITC-lysozyme in cytosol facilitated by PEI. Limited uptake of FITC-






This study has shown an efficient way of targeted cancer cell eradication by intracellular 
delivery of GzmB using HA-EGCG conjugates. Self-assembled HA-EGCG/GzmB/PEI nanogel 
complexes were prepared by simple mixing and they demonstrated targeted toxicity against 
CD44 overexpressing HCT-116 cells but not CD44 negative cells. The toxicity was attributed to 
GzmB mediated apoptosis, indicating the successful intracellular delivery of GzmB by HA-
EGCG conjugates. As a result of EGCG’s ability to interact with many bioactive molecules, it is 
expected that our approach can be extended to delivery of other cytotoxic agents, making HA-
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Chapter 4: Targeted gene delivery based on 








Gene therapy is a promising treatment for many diseases, including cancer; for example, 
the tumor suppressor gene p53 has been used for the treatment of ovarian carcinoma [1, 2]. 
Hence, many gene delivery vehicles have been developed for cancer gene therapy. Non-viral 
vectors have been garnering increasing interest in recent years due to their non-immunogenicity, 
ease of modification and scalability [3-5]. Among them, polyethyleneimine (PEI) is one of the 
most widely used because of its high transfection efficiency [6, 7]. However, there are several 
limitations to the usage of PEI - 1) significant toxicity as its high positive charge density disrupt 
cell membranes [8, 9]. 2) non-specific interactions with blood components such as serum 
proteins due to the surface charge of PEI/DNA complex [10]. 3) aggregation of PEI/DNA 
complexes under physiological conditions [11, 12]. Therefore, numerous approaches were 
explored to modify PEI [13-15] to reduce toxicity, decrease non-specific interactions with 
proteins and minimize aggregation. To target a specific disease such as cancer, recognition 
motifs have also been incorporated to achieve selective delivery of genetic materials into cancer 
cells [16]. 
 Hyaluronic acid (HA) is a glycosaminoglycan composed of repeating disaccharide units 
of N-acetyl-D-glucosamine and D-glucuronic acid. It is a main component of the extracellular 
matrix (ECM) and is involved in many cellular functions including cell proliferation, 
differentiation and migration [17, 18]. Since HA possesses attractive properties such as 
biodegradability and biocompatibility, it has been integrated in designs of vectors for drug/gene 
delivery [19]. More importantly, HA has been chosen because of its ability to interact with CD44 
that is overexpressed on many cancer cells [20, 21]. To exploit the HA-CD44 targeting property, 
many HA-based delivery systems have been developed to transport therapeutics such as proteins, 
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peptides and nucleotides [22, 23] into cancer cells specifically. In particular for gene delivery, 
HA has been shown to form a ternary complex with PEI/DNA because of the ionic interactions 
between carboxyl residues and amine groups of PEI. These HA-coated PEI/DNA ternary 
complexes were demonstrated to enhance gene transfer into specific cells by CD44 targeting [24, 
25]; as well as reduce toxicity [26] and minimize aggregation by shielding of positive charges 
[27].  
 In this study, we describe the synthesis of novel HA-EGCG conjugates for the targeted 
delivery of DNA into cancer cells. EGCG is a major constituent of green tea catechins and it has 
been shown to interact with many macromolecules including DNA via hydrogen bonding, π-π 
stacking and hydrophobic interactions [28-30]. Thus we hypothesize that the conjugation of 
EGCG to the HA backbone would enable HA-EGCG conjugates to interact more favorably with 
DNA than HA alone. It is expected that the strong binding interactions between HA-EGCG and 
PEI/DNA complex would lead to the formation of stable HA-EGCG/PEI/DNA nanogel 
complexes (Figure 4-1 a). This allows the HA-EGCG nanogel complexes to be internalized 
efficiently into CD44 overexpressing cancer cells via receptor-mediated endocytosis, thereby 





Figure 4-1. Schematic representation of HA-EGCG/PEI/DNA nanogel complex formation and application for 
targeted gene delivery. (a) Binary complex between PEI and DNA was first prepared, followed by addition of 
HA-EGCG conjugate. (b) Presentation of HA-EGCG on outer surface of complex facilitates uptake of 




4.2. Materials and Methods 
4.2.1. Materials 
Hyaluronic acid (HA, 90 kDa) was kindly donated by JNC Corporation (Tokyo, Japan). 
Tetrahydrofuran (THF), methanesulfonic acid (MSA), 2,2-diethoxyethylamine (DA), N-
hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride 
(EDC⋅HCl), branched polyethyleneimine (PEI) were all obtained from Sigma-Aldrich. EGCG 
(TEAVIGO) was purchased from DMS Nutritional Products Ltd (Switzerland). Phosphate buffer 
saline (PBS, 150 mM, pH 7.3) and all cell culture media were supplied by the media preparation 
facility in Biopolis, Singapore. 
4.2.2. Synthesis of HA-EGCG Conjugate 
The HA-EGCG conjugate was synthesized in a two-step process established previously 
in our laboratory [31].  
1) Synthesis of ethylamine-bridged EGCG dimers. In a glass vial containing 1.2 ml of 
cold MSA:THF (1:5 (v/v)) mixture, 145 μl of DA (1 mmol) was added while stirring. The 
resulting mixture was transferred dropwise to EGCG (2.29 g, 5 mmol), which was dissolved in 
3.8 ml of THF and 1.7 ml of MSA, and stirred overnight in the dark at room temperature. Next 
day, the solvent (THF) was removed by evaporation and further dried under vacuum overnight at 
room temperature. The dried products were dissolved in 10 ml of H2O and the unreacted EGCG 
were removed by extraction with 10 ml of ethyl acetate using a separation funnel. Unreacted 
EGCG moved to the organic phase while the ethylamine-bridged EGCG dimers remained in the 
aqueous phase. The extraction procedure was repeated until no free EGCG was detected in the 
aqueous phase using a Waters Acuity UPLC-MS. The concentration of the purified ethylamine-
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bridged EGCG dimer in the aqueous phase was determined by absorbance at 274 nm and was 
found to be 84 mg/ml (yield = 88 %). The dimers were stored at -80 °C. 
2) Synthesis of HA-EGCG conjugates. Ethylamine-bridged EGCG dimers were 
conjugated to HA by a typical carbodiimide/active ester-mediated coupling reaction [32]. HA 
(250 mg, 0.62 mmol) was dissolved by stirring in 20.2 ml of 0.4 M MES buffer (pH 5.2) with 2.5 
ml of DMF. Next, NHS (89 mg, 0.78 mmol) and ethylamine-bridged EGCG dimers (0.205 mmol 
in 2.33 ml of H2O) were added to the reaction mixture. Then, EDC⋅HCl (150 mg, 0.78 mmol) 
was added and the pH of the reaction was adjusted to 4.7. The reaction mixture was purged 
vigorously with N2 for 10 min and then incubated in the dark overnight under N2 at room 
temperature. The HA-EGCG conjugates were purified by precipitation using a previously 
established method with some modifications [32, 33]. Briefly, 125 ml of H2O and 16.7 ml of 5 
M NaCl solution were added to the reaction mixture and the pH was lowered to 3 with 10 M HCl 
solution. Then, 310 ml of ethanol was added while stirring. Under these conditions the HA-
EGCG conjugates formed slurry precipitates which were collected by centrifugation (6000 rcf, 5 
min). After decanting the supernatant, the precipitates were re-dissolved in 250 ml of water. 
After adding 33 ml of 5 M NaCl solution and the pH adjusted to 3, 620 ml of ethanol was added. 
The precipitates were collected by centrifugation and re-dissolved in 500 ml of H2O. After 
adding 67 ml of 5 M NaCl solution and lowering the pH to 3, 1.24 L of ethanol was added. The 
precipitates were again collected by centrifugation and re-dissolved in 300 ml of H2O. The 
conjugates were then dialyzed (Mw cut-off: 3500 Da) against H2O in N2 atmosphere overnight. 
Finally, the purified HA-EGCG conjugates were lyophilized. The yield was 185 mg (74 %). To 
calculate the degree of substitution (number of EGCG dimers conjugated for every 100 
disaccharide units), the conjugates were dissolved at 0.1 mg/ml in water and UV-Vis spectrum 
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was recorded with a Hitachi U-2810 spectrometer. The amount of EGCG contained in the 
conjugate was determined by comparing the absorbance at 274 nm to the EGCG standard curve.  
4.2.3. Preparation of various complexes 
DNA plasmid (pEGFP-C1, 4.7 kbp) encoding for GFP was obtained from Clontech 
Laboratories, Inc. (CA, USA). PEI/DNA binary complexes were formed at various molar ratios 
of the amine group of PEI to the phosphate group on DNA (N/P ratios) by adding appropriate 
volumes of PEI to DNA in water. The solution was mixed gently and allowed to stand at room 
temperature for 15 min. For the formation HA or HA-EGCG nanogel complexes, HA or HA-
EGCG were then added to the solution at designated molar ratios of the carboxyl group of HA to 
the phosphate group on DNA (C/P ratios) ranging from 0.1 to 10 and incubated for a further 30 
min.  
4.2.4. Hydrodynamic size and zeta potential measurements 
A Malvern Zetasizer Nano ZS (Worcestershire, UK) was used to measure the 
hydrodynamic size and zeta potential of all the complexes. For size measurements, complexes 
were prepared accordingly with 1 µg of DNA and diluted to 1 ml final volume with MilliQ 
water. To determine the zeta potentials, samples were dispersed in diluted 10 mM NaCl instead. 
All measurements were performed in triplicates and the results were reported as mean ± s.d. 
4.2.5. Agarose gel electrophoresis 
The ability of all the complexes to condense plasmid DNA was assessed through the 
elimination of electrophoretic mobility using agarose gel electrophoresis. PEI/DNA binary 
complex at N/P 30 and HA or HA-EGCG/PEI/DNA nanogel complexes of various C/P ratios 
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containing plasmid 1 µg DNA were prepare with a final volume of 10 µl. The samples were then 
loaded in a 1.2 % agarose gel containing the SYBR® Safe dye (Invitrogen). Subsequently, the 
gel was run in 1 × Tris-acetate-EDTA (TAE) buffer at a constant voltage (100 V) for 25 min. 
Images were then captured with a Versadoc 4000 MP instrument (Bio-Rad Laboratories, 
Singapore). To examine the stability of the complexes, heparin was added (final concentration 1 
mg/ml) to the complexes and further incubated for 30 min prior to gel electrophoresis. 
4.2.6. GFP expression assay 
Human embryonic kidney (HEK293) and human colorectal carcinoma (HCT-116) cells 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) and McCoy’s 5A medium 
respectively, completed with 10 % (v/v) fetal bovine serum (FBS) and 1 % (v/v) 
penicillin/streptomycin at 37 °C with 5 % CO2. For both cell types, 100,000 cells were added 
into each well of 24-well plates to attach for 24 h. On the day of transfection, 100 μl of PEI/DNA 
binary at various N/P ratios were prepared as above and then added to each well. For HA or HA-
EGCG nanogel complexes, N/P ratio was fixed at 30 and the HA or HA-EGCG amounts added 
were calculated based on designated C/P ratios ranging from 0.1 to 10. The transfection 
experiments were performed in the presence of 10 % FBS. The amount of DNA introduced into 
each well was fixed at 1.5 μg. On the designated day of transfection analysis (72 h after 
transfection for HCT-116 and 48 h for HEK293), the cells were harvested and suspended in PBS 
for flow cytometry analysis (LSR II, BD Bioscience, CA, USA). 10,000 cells were gated and the 
percentage of cells expressing GFP was reported as mean ± s.d. of triplicates at least. Cells were 
defined to be positive for GFP if they fell within the gating region pre-set to include < 2 % of 
untreated control cells. At the same time, quantitative GFP expression was also estimated by 
mean fluorescence intensity. Images of GFP-positive cells were taken with an inverted 
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fluorescence microscope (IX71, Olympus Corporation, Tokyo, Japan) fitted with a DP70 camera 
(Olympus) at 4 × magnification.  
To assess the HA receptor mediated uptake in cancer cells; a competitive inhibition assay 
was used in which the cells were pretreated with HA to saturate the receptors. Dextran was used 
as a control. After 1 h pretreatment, the complexes were then added to the cells. Percentage of 
cells transfected was evaluated by flow cytometry.  
4.2.7. In vitro cytotoxicity assay 
For both HEK293 and HCT-116 cells, 15,000 cells were seeded in each well of a 96-well 
microplate and incubated for one day to allow for cell attachment. The next day, cells were 
subjected to similar treatments as aforementioned in the GFP transfection experiment, albeit with 
volumes scaled down proportionally to 20 μl per well.  Final DNA amount introduced into each 
well was 0.3 μg. Cell viability was evaluated by the AlamarBlue® assay (Invitrogen) at 
designated time-points similar to the GFP transfection assay. Briefly, cells were gently washed 
with PBS once before fresh medium with AlamarBlue® (10 % (v/v)) was added. The cells were 
incubated for another 2 h and fluorescence was measured using a Tecan Infinite Microplate 
Reader (Ex/Em: 545/590 nm). Cell viability was expressed as a percentage of untreated control 
cells and data was reported as mean ± s.d. of quadruplicates. 
4.2.8. CD44 evaluation by flow cytometry  
 One million cells of each type were harvested and split into two equal portions. One was 
incubated with CD44 antibody (2 mg/ml) and the other incubated with the isotype control for 15 
min at room temperature. After that they were washed 3 times with cold PBS with 10 % (v/v) 
FBS before flow cytometry analysis (LSR II, BD Bioscience, CA, USA). 
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4.2.9. Intracellular trafficking and cellular uptake  
 DNA labelling was done following the protocol provided by DNA labelling kit (Cy 5 
Label IT® Tracker™ Intracellular Nucleic Acid Localization Kit (Mirus, USA). For intracellular 
trafficking study, HCT-116 cells were seeded in 8-well chamber slides (Lab-Tek®) at the density 
of 20 000 per well and left to attach for 24 h. The complexes were prepared with Cy 5-labelled 
pDNA (0.5 μg DNA per well) and added to the cells. At the designated time-points, the medium 
was removed and cells were washed with PBS thrice and fixed with 4 % paraformaldehyde. 
After that, cell nuclei were labelled with 4, 6-diamidino-2-phenylindole (DAPI) and the cells 
were visualized under a confocal laser scanning microscope (Zeiss LSM 510 META). 
 To quantify cellular uptake, HCT-116 cells were seeded in 24-well plates and complexes 
containing Cy 5-labelled plasmid DNA were prepared in the same manner as the transfection 
experiment and added to the cells. At the designated time-points, the fluorescent DNA-
containing cells were collected and and suspended in PBS and evaluated by flow cytometry 
(LSR II, BD Bioscience, CA, USA). Uptake levels of complexes in the cells were analyzed with 
a gated population of living 5,000 cells. 
4.2.10. Statistical analysis  
Statistical analysis was determined by analysis of variance tests (ANOVA) using Microsoft 
Excel. Data sets were compared using two-tailed, unpaired Student’s t-tests. And a p value of < 0.05 was 




4.3. Results and discussion 
4.3.1. Synthesis of HA-EGCG conjugates  
HA-EGCG  conjugates were synthesized as described in our previous report [31]. First, 
ethylamine-bridged EGCG dimer was synthesized by the coupling reaction of 2,2-
diethoxyethylamine onto A-ring of EGCG. Subsequently, ethylamine-bridged EGCG dimer was 
conjugated to HA by conventional carbodiimide reaction between amine group of ethylamine-
bridged EGCG dimer and carboxyl residue of HA. By comparing the UV absorbance of HA-
EGCG against a standard curve for EGCG with wavelength peak of 274 nm, the EGCG content 
could be determined and the degree of substitution (number of EGCG dimers conjugated for 
every 100 disaccharide units) was estimated to be 2.5.  
4.3.2. Optimization of PEI/DNA N/P ratios for transfection 
To determine the optimal condition for PEI/DNA binary complexes, the transfection 
efficiencies and toxicities of binary complexes at escalating N/P ratios were evaluated in two 
different cell lines – a human colorectal carcinoma cell line - HCT-116 and a normal human 
embryonic kidney cell line - HEK293. In general, increasing the N/P ratio led to an increase in 
the percentage of cells transfected as well as a decrease in cell viability in both cell lines. In 
HCT-116 cells, the maximum transfection efficiency of 15.6 % was detected at N/P ratio of 30 
with a corresponding cell viability of 84.8 % (Figure 4-2 a). The N/P ratio of 40 resulted in lower 
transfection efficiency and higher toxicity. For HEK293 cells, we observed that PEI/DNA 
complex at N/P ratio of 30 transfected 73.8 % of cells while maintaining 80.2 % of cell viability 
(Figure 4-2 b). Significant cell death was observed at N/P ratio of 40. Therefore the optimal N/P 
ratio of 30 was chosen for subsequent formation of nanogel complexes.  
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Figure 4-2. Optimization of PEI/DNA binary complexes for transfection. Percentage of cells transfected and 
cell viability of (a) HCT-116 cells and (b) HEK293 cells treated with PEI/DNA complex at various N/P ratios.  
  
4.3.3. Characterizations of HA-EGCG nanogel complexes  
We prepared HA-EGCG nanogel complexes by simply adding HA-EGCG conjugates to 
the pre-formed PEI/DNA binary complexes at N/P ratio of 30. HA complexes were similarly 
prepared as comparison. Various amounts of HA-EGCG or HA were added based on the 
carboxylate anion to DNA phosphate ratio (C/P ratio) within the range of 0.1 to 10. The size and 
zeta potential of the nanogel complexes were then measured. All of the complexes were found to 
be between 100-200 nm (Figure 4-3 a). The zeta potential, which is an indication of the surface 
charge of the complexes, decreased as a function of increasing HA-EGCG C/P ratios (Figure 4-3 
b). This drop is due to the neutralization of the positive charges of PEI by the negatively charged 
carboxylate anions on HA. Interestingly, at the C/P ratio of 10, HA-EGCG nanogel complex had 
significantly lower surface charge than HA complexes (-7.5 mV vs. 1.2 mV). This indicates that 
HA-EGCG could probably provide a more stable anchorage onto the surface of the PEI/DNA 
binary complex than HA, contributing to the reduction in surface charge.  
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Figure 4-3. (a) Hydrodynamic sizes and (b) zeta potentials of HA-EGCG/PEI/DNA nanogel complexes of 
increasing C/P ratios.  
 
 
4.3.4. Stability of HA-EGCG nanogel complexes  
It has been well-documented that the presence of negatively-charged serum proteins 
would destabilize PEI/DNA complexes via adsorption and exchange reactions [34, 35]. To 
evaluate the stability of the complexes by assessment of DNA mobility via gel electrophoresis, 
all the complexes were challenged in the serum-simulated condition with the introduction of 
heparin. Figure 4-4 illustrates the results. In the absence of heparin, all the complexes showed 
strong DNA binding ability and total inhibition of DNA migration. Addition of heparin resulted 
in DNA liberation from all the HA/PEI/DNA complexes at various C/P ratios and PEI/DNA 
binary complexes. In contrast, complete DNA release was only observed in C/P ratios (0.1, 0.5 
and 2) for HA-EGCG/PEI/DNA nanogel complexes. Partial release of DNA was seen in C/P 
ratio of 5 showing diminished DNA band intensity while DNA release was completely 
suppressed in C/P ratio of 10. This suggests that increasing HA-EGCG concentrations led to 
stronger interactions between HA-EGCG and PEI/DNA complex, contributing to enhanced 
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stability. As such, HA-EGCG nanogel complexes could possibly maintain their integrities more 
effectively in serum condition than the other complexes. 
 
Figure 4-4. Agarose gel electrophoresis retardation assay of HA-EGCG/PEI/DNA nanogel complexes 
prepared at different C/P ratios. PEI/DNA binary complex at N/P ratio of 30 and HA/PEI/DNA complexes 
were used as comparison. Top panel shows complexes with no heparin treatment while bottom panel displays 
complexes treated with heparin (final concentration 1 mg/ml) for 30 min prior to gel electrophoresis. 
 
4.3.5. Transfection efficiency and cytotoxicity of HA-EGCG nanogel complexes 
Prior to investigating the in vitro transfection efficiency of HA-EGCG nanogel 
complexes, the two cell lines HCT-116 and HEK293 were assessed for CD44 expression. 
Similar to many cancer cells, a high proportion (99.4 %) of HCT-116 cells was found to express 







Table 4-1. CD44 expression level in HCT-116 and HEK cells. 
Cell line Cell type CD44 expression (%) 
HCT-116 Human colorectal carcinoma 99.4 
HEK293 Human embryonic kidney 3.2 
 
Next we evaluated the transfection efficiency of HA-EGCG nanogel complexes in the 
CD44 overexpressing HCT-116 cells. The PEI/DNA binary complex at N/P ratio of 30 and 
HA/PEI/DNA complexes were used as comparison. A range of C/P ratios from 0.1 to 10 were 
examined. Figure 4-5 depicts the representative fluorescent microscopic images of GFP-
expressing cells corresponding to the respective transfection conditions. The extent of GFP-
positive cells transfected was quantified by flow cytometry (Figure 4-6). We observed that both 
HA and HA-EGCG nanogel complexes demonstrated significantly enhanced transfection 
efficiencies compared to PEI/DNA binary complexes at N/P ratio of 30 (Figure 4-6 a). In 
particular, HA-EGCG nanogel complex at C/P ratio of 0.5 and HA complex at C/P ratio of 5 
successfully transfected 43.7 % and 37.2 % of HCT-116 cells respectively, which is about 2-fold 
increment over that of PEI/DNA binary complex at 19.0 %. The rise in transfection efficiency 
could probably be attributed to enhanced cellular uptake of complexes via CD44 mediated 
endocytosis. In addition, while the percentage of cells transfected increased as a function of 
increasing C/P ratios for both HA-EGCG nanogel complexes and HA complexes, we noted that 
this increase for HA complex was shifted toward much higher C/P ratios as compared to HA-
EGCG nanogel complex. It is worth mentioning that the maximum transfection mediated by HA-
EGCG nanogel complex at C/P ratio of 0.5 was superior to that mediated by HA complex at C/P 
ratio of 5 even though the amount of polymer used was 10 times lower. This could possibly be 
explained by the enhanced stability of the HA-EGCG nanogel complexes. Considering that all 
transfection experiments were performed in serum existing condition, the HA complexes were 
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more likely to be dissociated by the negatively charged serum proteins, resulting in lower gene 
delivery efficiency. Quantitative assessment of GFP expression by fluorescence intensity 
revealed similar trends as the percentage of cells transfected with GFP plasmid (Figure 4-6 b). 
Overall this in vitro transfection study clearly demonstrated that HA-EGCG nanogel complexes 
were more efficient than both PEI/DNA binary complex and HA complexes in transfecting 




Figure 4-5. Representative images of distribution of GFP-positive cells after being transfected with various 
complex formulations; (a) PEI/DNA binary complex at N/P ratio of 30, (b) HA/PEI/DNA complexes and (c) 
HA-EGCG/PEI/DNA nanogel complexes at the indicated C/P ratios. Scale bar = 500 µm. 
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Figure 4-6. Transfection efficiency of HA-EGCG/PEI/DNA nanogel complexes in HCT-116 cells with 
PEI/DNA binary complex at N/P ratio of 30 and HA/PEI/DNA complexes as comparison. (a) Percentage of 
cells successfully transfected with GFP plasmid; (b) Mean fluorescence intensity of GFP expressed in the 
transfected cells. * p < 0.005; ** p < 0.0005; *** p < 0.00005. 
To examine the mechanism of uptake of the HA-EGCG nanogel complexes, transfection 
experiment was performed following free HA pre-incubation to block the receptors. We 
observed that percentage of cells transfected decreased proportionately with increasing free HA 
concentration, from 43.7 % with 0 mg/ml HA to 4.1 % with 2 mg/ml HA pre-treatment (Figure 
4-7). This suggests that HA-receptor mediated endocytosis facilitated intracellular delivery of 
HA-EGCG nanogel complexes into HCT-116 cells.  
 
Figure 4-7. Transfection efficiency of HA-EGCG/PEI/DNA nanogel complex at C/P ratio of 0.5 in HCT-116 
cells pre-incubated with free HA at increasing concentrations. * p < 0.05. 
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Given that the enhanced transfection observed in HCT-116 cells was mediated by CD44, 
HA-EGCG nanogel complexes could be exploited for cancer cell-specific transfection. To 
investigate the specificity of nanogel mediated gene delivery, transfection efficiencies of various 
complexes were then evaluated on low CD44 expressing normal HEK293 cells. From the results 
on Figure 4-8, it is evident that both the percentage of cells transfected and the fluorescence 
intensity were highest for PEI/DNA binary complex. Both HA and HA-EGCG nanogel 
complexes demonstrated lower transfection efficiencies at all the C/P ratios tested. It is generally 
accepted that the cationic charges on PEI facilitate cellular uptake through electrostatic 
interactions with the negatively charged cell membrane [9, 36]. Therefore in the absence of 
CD44, the lower surface charges of HA and HA-EGCG nanogel complexes probably resulted in 
retardation of complex internalization, leading to reduction in transfection efficiency. This 
finding clearly confirmed the specificity of HA-EGCG nanogel complexes to mediate superior 
gene delivery efficiency in high CD44 expressing cancer cells.  
Figure 4-8. Transfection efficiency of HA-EGCG/PEI/DNA nanogel complexes in HEK293 cells with 
PEI/DNA binary complex at N/P ratio of 30 and HA/PEI/DNA complexes as comparison. (a) Percentage of 
cells successfully transfected with GFP plasmid; (b) Mean fluorescence intensity of GFP expressed in the 
transfected cells. 
 
Next, the in vitro cytotoxicity of the complexes was assessed in both HCT-116 and 
HEK293 cells. We observed that HA-EGCG nanogel complexes did not result in significant 
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toxicity in both cell types at all the C/P ratios tested (Figure 4-9). In particular, at the optimal 
transfection C/P ratio of 0.5 for HA-EGCG nanogel complexes, the cell viabilities of both cell 
types were maintained above 80 %.  
Figure 4-9. Effect of HA-EGCG/PEI/DNA nanogel complexes at the indicated C/P ratios on the cell viabilities 
of (a) HCT-116 and (b) HEK293 cells. 
4.3.6. Cellular uptake of HA-EGCG nanogel complexes  
To elucidate the effect of CD44 on cellular uptake, we incubated HCT-116 cells with 
various complexes containing plasmid DNA labelled with fluorescent dye - Cy 5 and observed 
the intracellular trafficking of complexes. Much stronger and more widespread fluorescence was 
observed in cells treated with HA-EGCG nanogel complex as compared to both PEI/DNA binary 
complex and HA complex after 1 and 4 h incubation (Figure 4-10). In addition, there was also a 
greater extent of nuclear (stained blue) co-localization of labelled DNA in HA-EGCG complex 
treated cells at 4 h. A quantitative analysis of DNA uptake by flow cytometry confirmed the 
visual findings (Figure 4-11 a). HA-EGCG nanogel complex demonstrated the highest mean 
fluorescence at both 1 and 4 h. In particular, at 4 h post-treatment the extent of uptake was 1.7 
times of PEI/DNA complex and 1.3 times of HA complex. This indicates that CD44-mediated 
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endocytosis indeed led to increased uptake of the complexes, which in turn translated to 
improved transfection efficiency, as shown in  (Figure 4-6 a). 
Figure 4-10. Intracellular distribution of Cy 5-labelled DNA in HCT-116 cells at 1 h (a, b, c) and 4 h (d, e, f). 
Images a, d represent cells treated with PEI/DNA binary complex at N/P ratio of 30; b, e represent cells 
treated with HA/PEI/DNA complex at C/P ratio 0.5 and c, f represent cells treated with HA-EGCG/PEI/DNA 
nanogel complex at C/P ratio of 0.5.  Scale bar = 20 nm. 
Figure 4-11. Mean fluorescence of cells treated with (a) PEI/DNA binary complex at N/P ratio of 30, 
HA/PEI/DNA complex and HA-EGCG/PEI/DNA nanogel complex both at C/P ratio of 0.5 at 1 and 4 h and 
(b) HA/PEI/DNA and HA-EGCG/PEI/DNA nanogel complexes at the indicated C/P ratios. Mean fluorescence 
of samples was normalized against mean fluorescence of PEI/DNA binary complex at N/P ratio of 30 at the 
particular time-point. # p < 0.05 versus PEI/DNA binary complex at N/P ratio of 30 at 4 h. * p < 0.05; ** p < 
0.001, *** p < 0.0005.  
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To understand the effect of increasing HA/HA-EGCG on cellular uptake, HCT-116 cells 
were incubated with HA and HA-EGCG nanogel complexes containing Cy 5 labelled-DNA at 
different C/P ratios for 4 h and DNA internalization was subsequently evaluated by fluorescence 
measurements (Figure 4-11 b). We observed that internalization of HA-EGCG nanogel 
complexes at all C/P ratios were significantly higher than PEI/DNA binary complex at N/P ratio 
of 30. Furthermore, increasing HA-EGCG concentration also promoted internalization of the 
HA-EGCG complexes probably via HA receptor-mediated uptake. In particular, the uptake was 
enhanced by about 4-fold as C/P ratio escalated from 0.1 to 10. Interestingly, we noted that the 
increment in the extent of internalization of HA-EGCG nanogel complexes as a function of C/P 
ratio did not correlate well with the transfection results. Percentage of cells transfected reached a 
peak at C/P ratio 0.5 and declined drastically as C/P ratio increased to 10. This implies that 
another step apart from cellular uptake was impeding gene transfer. Besides efficient 
internalization, unpacking of DNA from complexes followed by DNA migration into nucleus are 
also recognized to be critical for gene delivery [37]. From the gel retardation results we noted 
that the HA-EGCG nanogel complexes were highly stable and resistant to heparin treatment. 
That is probably due to the strong interactions between HA-EGCG and PEI/DNA complex, in 
particular the non-covalent interactions between EGCG and DNA. Thus we hypothesize that 
high stability may have inhibited complex disassembly and DNA release upon internalization of 
the nanogel complexes, leading to decrease in transfection efficiency at higher C/P ratios. 
Nevertheless, we expect that the enhanced stability of HA-EGCG nanogel complexes may be 
beneficial for in vivo cancer therapy application by maintain the integrity of the complexes when 
they are challenged by numerous serum proteins present in the blood stream. 
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 For HA complexes, we also observed a general increasing trend for cellular 
internalization as a function of increasing C/P ratios, although significant improvement over 
PEI/DNA binary complex NP at ratio of 30 was only observed at C/P ratios of 0.5 and 5. This 
suggests that the impact of CD44–mediated uptake in HA complexes was diminished compared 
to HA-EGCG. In addition, the cellular uptake of HA complexes was significantly lower than 
HA-EGCG nanogel complexes at all C/P ratios except 0.2. These observations could be 
attributed to the poor stability and serum compatibility of HA complexes, which may trigger 
complex disassembly even before encountering the HA receptors. Thus it can be concluded that 
in comparison to HA complexes, higher stability of HA-EGCG nanogel complexes facilitated 
more efficient uptake by CD44-mediated endocytosis, thereby contributing to enhancement in 






We have demonstrated an efficient method to deliver DNA into CD44 overexpressing 
cancer cells specifically using HA-EGCG nanogel complex. Self-assembled HA-
EGCG/PEI/DNA nanogel complexes were prepared by simple mixing. Strong interactions 
between HA-EGCG and PEI/DNA gave rise to increased stability of complexes. At the optimal 
HA-EGCG to PEI charge ratios, these nanogel complexes achieved significant enhancement in 
gene transfection than PEI/DNA binary complexes and HA/PEI/DNA complexes in CD44 
overexpressing HCT-116 cancer cells. The improvement in transfection was attributed to 
increased cellular uptake imparted by CD44-mediated endocytosis. High stability of the nanogel 
complexes also facilitated efficient internalization and gene transfer in serum existing condition. 
Since the HA-EGCG nanogel complexes successfully mediated targeted delivery of DNA to 
CD44 overexpressing cancer cells, we expect that this carrier could also enable the delivery of 
suicide genes to eradicate these cells specifically. This makes HA-EGCG nanogel complex a 
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With the advent of nanotechnology, we have witnessed immense progress in the design 
of DDS for anticancer drugs. However, out of the many DDS reported in literature, few have 
been successfully translated into clinical therapies. Some of the limitations include lack of 
treatment efficacy and toxic side effects, which may arise as a result of failure to achieve optimal 
stability. Intermolecular interactions between the carrier and therapeutic cargo play a key role in 
influencing the stability of DDS. Green tea catechin, EGCG has the ability to interact with 
variety of bioactive molecules. Thus the objective of my thesis is to develop polymeric carriers 
based on EGCG for cancer therapy. Three different types of payloads were investigated – small 
molecule drug, Dox, cytotoxic protein GzmB as well as DNA. Two different EGCG based 
conjugate designs – PEG-EGCG and HA-EGCG were synthesized for the delivery of these 
payloads. In this thesis, the polymeric carriers were characterized extensively and evaluated in 
terms of their delivery efficiency. 
In Chapter 2, the formation of Dox-loaded PEG-EGCG micelles for tumor delivery was 
reported. Strong interactions between EGCG and Dox facilitated the formation of highly stable, 
nanosized micelles with a remarkably high drug loading capacity (~ 86 %). As a result of the 
high stability and minimal drug leakage in circulation, Dox-loaded PEG-EGCG micelle 
demonstrated reduced toxicity in vivo and a much elevated maximum tolerated dose compared to 
two clinically relevant Dox formulations - Dox and DOXIL. Most notably, Dox-loaded PEG-
EGCG micelle at 50 mg/kg achieved greater significant tumor growth inhibition as compared to 
optimal dosages of both Dox and DOXIL. This demonstrated that PEG-EGCG micelle can 
provide for an effective and safe carrier to deliver Dox for cancer therapy. 
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In Chapter 3, HA-EGCG conjugates were utilized for the targeted cancer cell eradication 
by intracellular delivery of the cytotoxic protein GzmB. Nanogel complexes comprising HA-
EGCG and GzmB were prepared based on self-assembly in aqueous solution, triggered by the 
interactions between EGCG moieties and GzmB. The nanogel complexes demonstrated targeted 
toxicity against CD44 overexpressing HCT-116 colon cancer cells. The toxicity was due to 
GzmB mediated apoptosis, thus confirming the successful delivered GzmB into the cytoplasm of 
the cancer cells.  
Besides small molecule drug and protein, EGCG could also interact favorably with DNA. 
Thus HA-EGCG conjugates were employed for the targeted intracellular delivery of DNA to 
cancer cells in Chapter 4. HA-EGCG nanogel complexes achieved significant enhancement in 
gene transfection than PEI/DNA binary complexes and HA complexes in CD44 overexpressing 
HCT-116 cancer cells. The improvement in transfection was attributed to increased cellular 
uptake imparted by CD44-mediated endocytosis. High stability of the nanogel complexes also 
facilitated efficient internalization and gene transfection. 
In summary, this thesis has clearly demonstrated that our design of EGCG based 
polymeric carriers could be used for the efficient and safe delivery of various types of drugs. 
These carriers provide a novel strategy in advancing cancer therapy. 
5.2. Future Directions 
• In Chapter 2 we observed that highly stable DOX-loaded PEG-EGCG micelles could 
inhibit tumor growth at elevated dosages without side effects. While high stability was 
advantageous in reducing leakage and nonspecific toxicity during circulation, it also 
inhibited free drug liberation upon carrier extravasation into the tumor vasculature, 
145 
 
contributing to poor antitumor activity. Hence, engineering tumor environment-
responsive Dox-loaded PEG-EGCG micelle is a useful strategy worth examining. Such a 
micelle carrier design could allow the triggered release of the drug once it has reached the 
tumor site. Many stimuli specific to the tumor environment have been identified. In 
particular, pH-responsive polymeric drug carriers, which could degrade in the acidic pH 
of the extracellular tumor environment, have been studied extensively. With respect to 
the PEG-EGCG conjugates, a pH-sensitive linker can be introduced in between PEG 
chain and EGCG moiety to facilitate micelle disintegration and on-site drug release. Such 
pH-responsive PEG-EGCG carriers have great potential to realize the ideal goal of tumor 
site specific delivery for cancer therapy.  
• Thus far we have examined the intracellular delivery of protein and DNA by HA-EGCG 
nanogel complexes in vitro. For practical cancer therapy applications, it is imperative to 
evaluate the therapeutic efficacy of this nanogel carrier using in vivo tumor models. One 
possible issue that may arise in the process of systemic administration is the preferential 
uptake of HA in organs such as the liver, where abundant HA receptors are expressed. To 
overcome this potential problem, the surface of the HA-EGCG nanogel complex could be 
appropriately PEGylated. It has been well-documented that PEG can impart a steric 
hindrance effect to repel attachment of proteins and other molecules, thus reducing the 
uptake and accumulation at liver site. In our experiment setting, the desired PEG surface 
coating may be achieved by adding various amounts of PEG-EGCG conjugates to the 
HA-EGCG nanogel complexes. These PEGylated nanogel complexes may provide a 
solution for bringing forward the in vitro delivery efficacy to in vivo therapeutic outcome. 
